Checked on CIViC,PMID,cDNA_Position,Multiple Mutants in Case,Mutation Event c.DNA.,Transcript Reference,Predicted Consequence Protein Change,variant_name,Mutation Type,Kindred Case (pedigree),Kindred Case,Confirmed De Novo,Phenotype,Reference,Age,Sex,Notes,Evidence Statements,Resolution,Input,Warnings,HGVS_transcript,HGVS_intronic_chr_context,HGVS_intronic_rsg_context,HGVS_RefSeqGene,HGVS_LRG,HGVS_LRG_transcript,HGVS_Predicted_Protein,HGVS_Genomic_GRCh37,GRCh37_CHR,GRCh37_POS,GRCh37_ID,GRCh37_REF,GRCh37_ALT,HGVS_Genomic_GRCh38,GRCh38_CHR,GRCh38_POS,GRCh38_ID,GRCh38_REF,GRCh38_ALT,Gene_Symbol,HGNC_Gene_ID,Transcript_description,Alt_genomic_loci
Yes,11483638,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H(c.292T>C),missense_variant,None,None,No,HP:0002666; HP:0009711; HP:0009713;HP:0010797; HP:0006770; HP:0008261; HP:0040277,"(Bender et al., 2001)",Unknown,Unknown,"This study was conducted to evaluate morbidity, specific clinical risk profile, and mortality among a series of 125 VHL c.292T>C mutation carriers (legendary nomenclature c.505 T>C used is paper). Frequently observed lesions were phaeochromocytoma (47%), retinal angiomas (36%), haemangioblastoma of the spine (36%), and haemangioblastoma of the brain (16%). Four patients developed renal cell carcinoma. VHL was symptomatic in 47% of subjects; 30% were asymptomatic despite the presence of at least one VHL related tumour and 23% of the carriers had no detectable VHL lesion. Of the 19 patients who had died (15%), 10 died of symptomatic VHL lesions. Overall penetrance by cumulative incidence functions is estimated at 48% by 35 years and 88% by 70 years. ","A total of 125 eligible subjects with germline c. 292T>C (authors used c.505T>C in the paper) mutation living in the district of Freiburg in Southern Germany underwent ophthalmoscopy and gadolinium enhanced magnetic resonance imaging of the brain, the spinal cord, and the abdomen to assess for VHL lesions. 64 out of the 125 subjects subjects were from 15 branches of the previously reported Black Forest family. Other subjects include 10 probands and 51 of their first-degree relatives who are also mutation carriers. Of the 125 sugjects, 96 (77%) had clinical manifestations of VHL. VHL was symptomatic in 47% of the patients, 30% were asymptomatic despite the presence of at least one VHL related tumour, and 23% of the subjects had no detectable VHL lesions. Estimation by cumulative incidence functions showed an overall VHL penetrance of 48% by the age of 35 and 88% by the age of 70, whereas estimation among symptomatic mutation carriers showed a penetrance of 30% by the age of 35 and 55% by the age of 70. There were no differences between males and females in the manifestation of single tumours or the overall penetrance of VHL. Among the 118 subjects with well documented adrenal gland status, 55 (47%) subjects developed phaeochromocytoma during their lifetime. Other frequent lesions were retinal angioma (36%), haemangioblastoma of the spine (36%), and, to a lesser extent, haemangioblastoma of the brain (16%). 4 patients developed renal clear cell carcinoma. 1 patient developed pancreatic islet cell tumour and pituitary adenoma. 1 patient developed small cell lung cancer. 2 patients developed testicular teratoma. ACMG: 'PP4' because the patients' phenotypes and family history are highly specidic for a disease with single genetic etiology.",Variant,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11273887,Unknown,No,Exon 1 del,NM_000551.3,Exon 1 Del,Exon 1 deletion,exon_loss_variant,unknown,unknown,No,HP:0000107; HP:0001737,"(Chatha et al., 2001)",E31Y0M; lk33Y0M,F,Mother,"A case report on a 31Y female with bilateral multiple renal cysts on US misdiagnosed as autosomal dominant polycystic kidney disease. The patient passed away from metastatic malignancy from an unknown origin. 2 years later, her daughter 18Y was diagnosed with cerebellar and retinal hemangioblastoma. Based on the clinical features and family history, VHL disease was suspected. Southern blot hybridization using the restriction enzymes PvulI, BglII, EcoRI, and BamHI  was used to detect a deletion within the VHL gene in Exon 1. ACMG: 'PP1' because of cosegregation with the disease in mother and daughter (multiple affected family members) in a gene definitively known to cause the disease.",Patient,NM_000551.3:Exon,"NM_000551.3:c.Exon: char 14: expected one of (, *, or a digit",,,,,,,,,,,,,,,,,,,,,,,
Yes,11273887,Unknown,No,Exon 1 del,NM_000551.3,Exon 1 Del,Exon 1 deletion,exon_loss_variant,unknown,unknown,No,HP:0010797; HP:0009711,"(Chatha et al., 2001)",E18Y0M,F,Daughter,,Patient,NM_000551.3:Exon,"NM_000551.3:c.Exon: char 14: expected one of (, *, or a digit",,,,,,,,,,,,,,,,,,,,,,,
Yes,22895882,Unknown,Yes,Unknown,Unknown,Unknown,deletion,deletion,None,None,No,HP:0001249,"(Hogan et al., 2012)",E17Y0M,M,,"Array Comparative Genomic Hybridization (array CGH) identified the cause of a proband's moderate mental retardation by discovery of a de novo deletion of chromosome 3p25.3 (deletion size between 1.03Mb to 1.25Mb).This deletion was shown to contain at least 25 genes including the VHL gene. The proband has a history of moderate mental retardation, behavioural and social problems. Investigations revealed a right cerebellar lesion, bulky pituitary gland, elevated growth hormone and elevated IGF-1 levels.",Patient,Unknown:Unknown,UNKNOWN is not part of genome build GRCh37,,,,,,,,,,,,,,,,,,,,,,,
Yes,11148816,Unknown,No,2kb del,NM_000551.3,Unknown,Unknown,deletion,1,1,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease were diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, pancreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. VHL gene deletion (deletion length range from 2-10kb) was found in 4 patients and their affected family members. ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:2kb,NM_000551.3:c.2kb: char 18: end of input,,,,,,,,,,,,,,,,,,,,,,,
Yes,11148816,Unknown,No,5kb del,NM_000551.3,Unknown,Unknown,deletion,2,2,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,,Tumour,NM_000551.3:5kb,NM_000551.3:c.5kb: char 18: end of input,,,,,,,,,,,,,,,,,,,,,,,
Yes,11148816,Unknown,No,10kb del,NM_000551.3,Unknown,Unknown,deletion,3,3,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,,Tumour,NM_000551.3:10kb,NM_000551.3:c.10kb: char 19: end of input,,,,,,,,,,,,,,,,,,,,,,,
Yes,11148816,Unknown,No,10kb del,NM_000551.3,Unknown,Unknown,deletion,4,4,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,,Tumour,NM_000551.3:10kb,NM_000551.3:c.10kb: char 19: end of input,,,,,,,,,,,,,,,,,,,,,,,
Yes,11148816,194,No,c.194C>G,NM_000551.3,p.Ser65Trp,S65W(c.194C>G),missense_variant,5,5,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disesase were diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoa 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, panccreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics.This patient with VHL-related retinal angiomatosis was found to have germline missence (c.194C>G) mutaion in the VHL gene. 1 other affected relative was also evaluated. ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.194C>G,,NM_000551.3:c.194C>G,,,NG_008212.3:g.5407C>G,LRG_322:g.5407C>G,LRG_322t1:c.194C>G,NP_000542.1(LRG_322p1):p.(Ser65Trp),NC_000003.11:g.10183725C>G,3,10183725,.,C,G,NC_000003.12:g.10142041C>G,3,10142041,.,C,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,208,No,c.208G>T,NM_000551.3,p.Glu70*,E70*(c.208G>T),stop_gained,6,6,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease was diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, pancreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. This patient with VHL-related retinal angiomatosis was found to have germline nonsense (c.208G>T) mutaion in the VHL gene. 1 other affected relative was also evaluated. ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.208G>T,,NM_000551.3:c.208G>T,,,NG_008212.3:g.5421G>T,LRG_322:g.5421G>T,LRG_322t1:c.208G>T,NP_000542.1(LRG_322p1):p.(Glu70Ter),NC_000003.11:g.10183739G>T,3,10183739,.,G,T,NC_000003.12:g.10142055G>T,3,10142055,.,G,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,233,No,c.233A>G,NM_000551.3,p.Asn78Ser,N78S (c.233A>G),missense_variant,8,8,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease was diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, pancreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. This patient with VHL-related retinal angiomatosis was found to have germline missence (c. 233A>G) mutaion in the VHL gene. ACMG evidence codes:  'PP4' because the patient's phenotype is highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.233A>G,,NM_000551.3:c.233A>G,,,NG_008212.3:g.5446A>G,LRG_322:g.5446A>G,LRG_322t1:c.233A>G,NP_000542.1(LRG_322p1):p.(Asn78Ser),NC_000003.11:g.10183764A>G,3,10183764,.,A,G,NC_000003.12:g.10142080A>G,3,10142080,.,A,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,278,No,c.278G>T,NM_000551.3,p.Gly93Val,G93V(c.278G>T),missense_variant,10,10,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease was diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, pancreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. This patient with VHL-related retinal angiomatosis was found to have germline missence (c.278G>T) mutaion in the VHL gene. ACMG evidence codes:  'PP4' because the patient's phenotype is highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.278G>T,,NM_000551.3:c.278G>T,,,NG_008212.3:g.5491G>T,LRG_322:g.5491G>T,LRG_322t1:c.278G>T,NP_000542.1(LRG_322p1):p.(Gly93Val),NC_000003.11:g.10183809G>T,3,10183809,.,G,T,NC_000003.12:g.10142125G>T,3,10142125,.,G,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,280,No,c.280G>T,NM_000551.3,p.Glu94*,E94*(c.280G>T),stop_gained,11,11,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease was diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, pancreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. This patient with VHL-related retinal angiomatosis was found to have germline nonsense (c.280G>T) mutaion in the VHL gene. 1 other affected relative was also evaluated. ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.280G>T,,NM_000551.3:c.280G>T,,,NG_008212.3:g.5493G>T,LRG_322:g.5493G>T,LRG_322t1:c.280G>T,NP_000542.1(LRG_322p1):p.(Glu94Ter),NC_000003.11:g.10183811G>T,3,10183811,.,G,T,NC_000003.12:g.10142127G>T,3,10142127,.,G,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,340,No,c.340+1G>A,NM_000551.3,Unknown,c.340+1G>A,splice_site_variant,12,12,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease were diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, pancreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. This patient with VHL-related retinal angiomatosis was found to have germline splicing (c.340+1G>A) mutaion in the VHL gene. ACMG evidence codes:  'PP4' because the patient's phenotype is highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.340+1G>A,,NM_000551.3:c.340+1G>A,NC_000003.11(NM_000551.3):c.340+1G>A,NG_008212.3(NM_000551.3):c.340+1G>A,NG_008212.3:g.5554G>A,LRG_322:g.5554G>A,LRG_322t1:c.340+1G>A,NP_000542.1(LRG_322p1):p.?,NC_000003.11:g.10183872G>A,3,10183872,.,G,A,NC_000003.12:g.10142188G>A,3,10142188,.,G,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,344,No,c.344A>G,NM_000551.3,p.His115Arg,H115R(c.344A>G),missense_variant,13,13,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease were diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, pancreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. Two patients with VHL-related retinal angiomatosis were found to have germline missence (c.344A>G) mutaion in the VHL gene. 1 other affected relative was also evaluated for one of the patients. ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.344A>G,,NM_000551.3:c.344A>G,,,NG_008212.3:g.9883A>G,LRG_322:g.9883A>G,LRG_322t1:c.344A>G,NP_000542.1(LRG_322p1):p.(His115Arg),NC_000003.11:g.10188201A>G,3,10188201,.,A,G,NC_000003.12:g.10146517A>G,3,10146517,.,A,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,344,No,c.344A>G,NM_000551.3,p.His115Arg,H115R(c.344A>G),missense_variant,14,14,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,,Tumour,NM_000551.3:c.344A>G,,NM_000551.3:c.344A>G,,,NG_008212.3:g.9883A>G,LRG_322:g.9883A>G,LRG_322t1:c.344A>G,NP_000542.1(LRG_322p1):p.(His115Arg),NC_000003.11:g.10188201A>G,3,10188201,.,A,G,NC_000003.12:g.10146517A>G,3,10146517,.,A,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,388,No,c.388G>T,NM_000551.3,p.Val130Phe,V130F(c.388G>T),missense_variant,15,15,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease were diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, pancreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. This patient with VHL-related retinal angiomatosis was found to have germline missence (c.388G>T) mutaion in the VHL gene. 2 other affected relatives also evaluated. ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.388G>T,,NM_000551.3:c.388G>T,,,NG_008212.3:g.9927G>T,LRG_322:g.9927G>T,LRG_322t1:c.388G>T,NP_000542.1(LRG_322p1):p.(Val130Phe),NC_000003.11:g.10188245G>T,3,10188245,.,G,T,NC_000003.12:g.10146561G>T,3,10146561,.,G,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,395,No,c.395A>C,NM_000551.3,p.Gln132Pro,Q132P(c.395A>C),missense_variant,16,16,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease were diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, pancreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. This patient with VHL-related retinal angiomatosis was found to have germline missence (c.395A>C) mutaion in the VHL gene. 3 other affected relatives also evaluated. ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.395A>C,,NM_000551.3:c.395A>C,,,NG_008212.3:g.9934A>C,LRG_322:g.9934A>C,LRG_322t1:c.395A>C,NP_000542.1(LRG_322p1):p.(Gln132Pro),NC_000003.11:g.10188252A>C,3,10188252,.,A,C,NC_000003.12:g.10146568A>C,3,10146568,.,A,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,452,No,c.452T>C,NM_000551.3,p.Ile151Thr,I151T(c.452T>C),missense_variant,17,17,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease were diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, pancreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. This patient with VHL-related retinal angiomatosis was found to have germline missence (c.452T>C) mutaion in the VHL gene. 3 other affected relatives also evaluated. ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.452T>C,,NM_000551.3:c.452T>C,,,NG_008212.3:g.9991T>C,LRG_322:g.9991T>C,LRG_322t1:c.452T>C,NP_000542.1(LRG_322p1):p.(Ile151Thr),NC_000003.11:g.10188309T>C,3,10188309,.,T,C,NC_000003.12:g.10146625T>C,3,10146625,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,463,No,c.463+3A>G,NM_000551.3,Unknown,c.463+3A>G,splice_site_variant,18,18,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease were diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, pancreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. This patient with VHL-related retinal angiomatosis was found to have germline splicing (c.463+3A>G) mutaion in the VHL gene. 1 other affected relative was evaluated. ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.463+3A>G,,NM_000551.3:c.463+3A>G,NC_000003.11(NM_000551.3):c.463+3A>G,NG_008212.3(NM_000551.3):c.463+3A>G,NG_008212.3:g.10005A>G,LRG_322:g.10005A>G,LRG_322t1:c.463+3A>G,NP_000542.1(LRG_322p1):p.?,NC_000003.11:g.10188323A>G,3,10188323,.,A,G,NC_000003.12:g.10146639A>G,3,10146639,.,A,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,481,No,c.481C>T,NM_000551.3,p.Arg161*,R161*(c.481C>T),stop_gained,20,20,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease were diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, pancreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. Two patients with VHL-related retinal angiomatosis were found to have germline missence (c.481C>T) mutation in the VHL gene. 1 other affected relative was also evaluated for one of the patients. ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.481C>T,,NM_000551.3:c.481C>T,,,NG_008212.3:g.13170C>T,LRG_322:g.13170C>T,LRG_322t1:c.481C>T,NP_000542.1(LRG_322p1):p.(Arg161Ter),NC_000003.11:g.10191488C>T,3,10191488,.,C,T,NC_000003.12:g.10149804C>T,3,10149804,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,481,No,c.481C>T,NM_000551.3,p.Arg161*,R161*(c.481C>T),stop_gained,21,21,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,,Tumour,NM_000551.3:c.481C>T,,NM_000551.3:c.481C>T,,,NG_008212.3:g.13170C>T,LRG_322:g.13170C>T,LRG_322t1:c.481C>T,NP_000542.1(LRG_322p1):p.(Arg161Ter),NC_000003.11:g.10191488C>T,3,10191488,.,C,T,NC_000003.12:g.10149804C>T,3,10149804,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,492,No,c.492G>T,NM_000551.3,p.Gln164His,Q164H(c.492G>T),missense_variant,22,22,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disesase were diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoa 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, panccreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. This patient with VHL-related retinal angiomatosis was found to have germline nonsense (c.492G>T) mutation in the VHL gene. 1 other affected relative was also evaluated. ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.492G>T,,NM_000551.3:c.492G>T,,,NG_008212.3:g.13181G>T,LRG_322:g.13181G>T,LRG_322t1:c.492G>T,NP_000542.1(LRG_322p1):p.(Gln164His),NC_000003.11:g.10191499G>T,3,10191499,.,G,T,NC_000003.12:g.10149815G>T,3,10149815,.,G,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,499,No,c.499C>T,NM_000551.3,p.Arg167Trp,R167W(c.499C>T),missense_variant,23,23,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disesase were diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoa 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, panccreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. This patient with VHL-related retinal angiomatosis was found to have germline nonsense (c.499C>T) mutaiton in the VHL gene. ACMG evidence codes:  'PP4' because the patient's phenotype is highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.499C>T,,NM_000551.3:c.499C>T,,,NG_008212.3:g.13188C>T,LRG_322:g.13188C>T,LRG_322t1:c.499C>T,NP_000542.1(LRG_322p1):p.(Arg167Trp),NC_000003.11:g.10191506C>T,3,10191506,.,C,T,NC_000003.12:g.10149822C>T,3,10149822,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,548,No,c.548C>A,NM_000551.3,p.Ser183*,S183*(c.548C>A),stop_gained,24,24,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disesase were diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoa 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, panccreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. Two patients with VHL-related retinal angiomatosis were found to have germline missence (c.548C>A) mutaiton in the VHL gene. ACMG evidence codes:  'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.548C>A,,NM_000551.3:c.548C>A,,,NG_008212.3:g.13237C>A,LRG_322:g.13237C>A,LRG_322t1:c.548C>A,NP_000542.1(LRG_322p1):p.(Ser183Ter),NC_000003.11:g.10191555C>A,3,10191555,.,C,A,NC_000003.12:g.10149871C>A,3,10149871,.,C,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,548,No,c.548C>A,NM_000551.3,p.Ser183*,S183*(c.548C>A),stop_gained,25,25,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,,Tumour,NM_000551.3:c.548C>A,,NM_000551.3:c.548C>A,,,NG_008212.3:g.13237C>A,LRG_322:g.13237C>A,LRG_322t1:c.548C>A,NP_000542.1(LRG_322p1):p.(Ser183Ter),NC_000003.11:g.10191555C>A,3,10191555,.,C,A,NC_000003.12:g.10149871C>A,3,10149871,.,C,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,593,No,c.593T>A,NM_000551.3,p.Leu198Gln,L198Q(c.593T>A),missense_variant,26,26,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease were diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, pancreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. This patient with VHL-related retinal angiomatosis was found to have germline nonsense (c.593T>A) mutaiton in the VHL gene. ACMG evidence codes:  'PP4' because the patient's phenotype is highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.593T>A,,NM_000551.3:c.593T>A,,,NG_008212.3:g.13282T>A,LRG_322:g.13282T>A,LRG_322t1:c.593T>A,NP_000542.1(LRG_322p1):p.(Leu198Gln),NC_000003.11:g.10191600T>A,3,10191600,.,T,A,NC_000003.12:g.10149916T>A,3,10149916,.,T,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,492,No,c.492G>C,NM_000551.3,p.Gln164His,Q164H(c.492G>C),missense_variant,28,28,No,HP:0009711,"(Kreusel et al., 2000)",E14Y0M,F,,41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinice between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. 14Y F present with retinal angioma with no personal or family history of other VHL lesion was foud to have Q164H (c.492G>C) missense mutation. Brother 27Y M with same mutation asymptomatic. ACMG evidence codes:  'PP4' because the patient's phenotype is highly specific for a disease with single genetic etiology.,Tumour,NM_000551.3:c.492G>C,,NM_000551.3:c.492G>C,,,NG_008212.3:g.13181G>C,LRG_322:g.13181G>C,LRG_322t1:c.492G>C,NP_000542.1(LRG_322p1):p.(Gln164His),NC_000003.11:g.10191499G>C,3,10191499,.,G,C,NC_000003.12:g.10149815G>C,3,10149815,.,G,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,210,No,c.210delG,NM_000551.3,p.Glu70Aspfs*89,E70Dfs*89 (c.210delG),frameshift_variant,7,7,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease was diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, pancreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. This patient with VHL-related retinal angiomatosis was found to have germline frameshift deletion (c.210delG) mutaion in the VHL gene.  ACMG evidence codes:  'PP4' because the patient's phenotype is highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.210delG,Removing redundant reference bases from variant description,NM_000551.3:c.210del,,,NG_008212.3:g.5423del,LRG_322:g.5423del,LRG_322t1:c.210del,NP_000542.1(LRG_322p1):p.(Glu70AspfsTer89),NC_000003.11:g.10183741del,3,10183740,.,AG,A,NC_000003.12:g.10142057del,3,10142056,.,AG,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,264,No,c.264G>C,NM_000551.3,p.Trp88Cys,W88C (c.263G>C),missense_variant,9,9,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease was diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, pancreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. This patient with VHL-related retinal angiomatosis was found to have germline missence (c.263G>C) mutaion in the VHL gene. ACMG evidence codes:  'PP4' because the patient's phenotype is highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.264G>C,,NM_000551.3:c.264G>C,,,NG_008212.3:g.5477G>C,LRG_322:g.5477G>C,LRG_322t1:c.264G>C,NP_000542.1(LRG_322p1):p.(Trp88Cys),NC_000003.11:g.10183795G>C,3,10183795,.,G,C,NC_000003.12:g.10142111G>C,3,10142111,.,G,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11148816,652,No,c.652T>A,NM_000551.3,Unknown,c.652T>A,intron_variant,27,27,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disesase were diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoa 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, panccreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. This patient with VHL-related retinal angiomatosis was found to have germline  (c.652T>A) mutaiton in the intron region of the VHL gene. ACMG evidence codes:  'PP4' because the patient's phenotype is highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.652T>A,Variant coordinate is out of the bound of CDS region (CDS length : 642),,,,,,,,,,,,,,,,,,,,,,,
Yes - p. needs to be updated on CIViC,11148816,464,No,c.464+1G>C,NM_000551.3,p.Val155Val,V155V (c.464+1G>C),splice_site_variant,19,19,No,HP:0009711,"(Kreusel et al., 2000)",Unknown,Unknown,,"41 non-related patients with retinal angiomatosis presenting in the Benjamin Franklin University Eye Clinic between 1988 to 1999 Germany were evaluated for the presence of other VHL lesions. VHL disease were diagnosed clinically in 33 patients based on the presence of other severe VHL lesions (spinal hemangioblastoma 45% prevalence, cerebellar hemangioblastoma 42% prevalence, renal cysts 39% prevalence, pancreatic cyst 39% prevalence, renal carcinoma 18% prevalence, PCC 18% prevalence). VHL germline mutations were identified in 27 out of 29 VHL families screened with molecular genetics. This patient with VHL-related retinal angiomatosis was found to have germline splicing mutation(c.464+1G>C) mutaiton in the VHL gene. ACMG evidence codes:  'PP4' because the patient's phenotype is highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.464+1G>C,The entered coordinates do not agree with the intron/exon boundaries for the selected transcript,,,,,,,,,,,,,,,,,,,,,,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16490522,194,No,c.194C>G,NM_000551.3,p.Ser65Trp,S65W(c.194C>G),missense_variant,1,1,No,HP:0009711,"(Kreusel et al., 2006)",E6Y0M,F,proband,"A 6 year-old girl was treated for symptomatic retinal capillary hemangioma. Family history revealed VHL disease in father and grandfather. VHL germlinie mutation c.194C>G (authors used c.407C>G in paper) were detected in the patient, her father and her sister. Investigation revealed spinal hemangioblastoma and kidney cysts in father. ACMG: 'PP4' because the patients' phenotypes and family history are highly specidic for a disease with single genetic etiology.",Patient,NM_000551.3:c.194C>G,,NM_000551.3:c.194C>G,,,NG_008212.3:g.5407C>G,LRG_322:g.5407C>G,LRG_322t1:c.194C>G,NP_000542.1(LRG_322p1):p.(Ser65Trp),NC_000003.11:g.10183725C>G,3,10183725,.,C,G,NC_000003.12:g.10142041C>G,3,10142041,.,C,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,16490522,194,No,c.194C>G,NM_000551.3,p.Ser65Trp,S65W(c.194C>G),missense_variant,1,1,No,HP:0010797; HP:0000107,"(Kreusel et al., 2006)",Unknown,M,father to proband,,Patient,NM_000551.3:c.194C>G,,NM_000551.3:c.194C>G,,,NG_008212.3:g.5407C>G,LRG_322:g.5407C>G,LRG_322t1:c.194C>G,NP_000542.1(LRG_322p1):p.(Ser65Trp),NC_000003.11:g.10183725C>G,3,10183725,.,C,G,NC_000003.12:g.10142041C>G,3,10142041,.,C,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29891534,429; 340+770,Yes,c.429C>T; c.340+770T>C,NM_000551.3,p.Asp143Asp,D143D(c.429C>T),synonymous_variant,"F1, II.1",1,No,HP:0001901,"(Lenglet et al., 2018)",E15Y0M,M,,"The authors identify a new VHL cryptic exon (termed E1') deep in intron 1 that is naturally expressed in many tissues. Mutations in E1' are identified in 7 families with erythrocytosis and in 1 large family with typical VHL disease but without any alteration in the other VHL exons. In this study, the authors show that the mutations in E1' induced a dysregulation of VHL splicing with excessive retention of E1' and were associated with a downregulation of VHL protein expression. In F1, II.1, two mutations are found on the VHL gene. c.429C>T results in a synonymous variant. c.340+770T>C results in Ser179Pro mutation on potential X1 protein encoded by E1' exon. The patient was diagnosed with erythrocytosis.",Patient,NM_000551.3:c.429C>T;NM_000551.3:c.340+770T>C,;,NM_000551.3:c.429C>T;NM_000551.3:c.340+770T>C,;NC_000003.11(NM_000551.3):c.340+770T>C,;NG_008212.3(NM_000551.3):c.340+770T>C,NG_008212.3:g.9968C>T;NG_008212.3:g.6323T>C,LRG_322:g.9968C>T;LRG_322:g.6323T>C,LRG_322t1:c.429C>T;LRG_322t1:c.340+770T>C,NP_000542.1(LRG_322p1):p.(Asp143=);NP_000542.1(LRG_322p1):p.?,NC_000003.11:g.10188286C>T;NC_000003.11:g.10184641T>C,3;3,10188286;10184641,.;.,C;T,T;C,NC_000003.12:g.10146602C>T;NC_000003.12:g.10142957T>C,3;3,10146602;10142957,.;.,C;T,T;C,VHL;VHL,HGNC:12687;HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA;Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",;
Yes,29891534,598; 340+770,Yes,c.598C>T; c.340+770T>C,NM_000551.3,p.Arg200Trp,R200W(c.598C>T),missense_variant,F2. II.1,2,No,HP:0001901,"(Lenglet et al., 2018)",E21Y0M,M,,"The authors identify a new VHL cryptic exon (termed E1') deep in intron 1 that is naturally expressed in many tissues. Mutations in E1' are identified in 7 families with erythrocytosis and in 1 large family with typical VHL disease but without any alteration in the other VHL exons. In this study, the authors show that the mutations in E1' induced a dysregulation of VHL splicing with excessive retention of E1' and were associated with a downregulation of VHL protein expression. In F2, II.1 and in F3, II.1 and II.2 two mutations are found on the VHL gene. c.598C>T results in a missense variant. c.340+770T>C results in p.Ser179Pro mutation on potential X1 protein encoded by E1' exon. The patients were diagnosed with erythrocytosis.",Patient,NM_000551.3:c.598C>T;NM_000551.3:c.340+770T>C,;,NM_000551.3:c.598C>T;NM_000551.3:c.340+770T>C,;NC_000003.11(NM_000551.3):c.340+770T>C,;NG_008212.3(NM_000551.3):c.340+770T>C,NG_008212.3:g.13287C>T;NG_008212.3:g.6323T>C,LRG_322:g.13287C>T;LRG_322:g.6323T>C,LRG_322t1:c.598C>T;LRG_322t1:c.340+770T>C,NP_000542.1(LRG_322p1):p.(Arg200Trp);NP_000542.1(LRG_322p1):p.?,NC_000003.11:g.10191605C>T;NC_000003.11:g.10184641T>C,3;3,10191605;10184641,.;.,C;T,T;C,NC_000003.12:g.10149921C>T;NC_000003.12:g.10142957T>C,3;3,10149921;10142957,.;.,C;T,T;C,VHL;VHL,HGNC:12687;HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA;Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",;
Yes,29891534,598; 340+770,Yes,c.598C>T; c.340+770T>C,NM_000551.3,p.Arg200Trp,R200W(c.598C>T),missense_variant,"F3, II.1",3,No,HP:0001901,"(Lenglet et al., 2018)",E0Y4M,M,,,Patient,NM_000551.3:c.598C>T;NM_000551.3:c.340+770T>C,;,NM_000551.3:c.598C>T;NM_000551.3:c.340+770T>C,;NC_000003.11(NM_000551.3):c.340+770T>C,;NG_008212.3(NM_000551.3):c.340+770T>C,NG_008212.3:g.13287C>T;NG_008212.3:g.6323T>C,LRG_322:g.13287C>T;LRG_322:g.6323T>C,LRG_322t1:c.598C>T;LRG_322t1:c.340+770T>C,NP_000542.1(LRG_322p1):p.(Arg200Trp);NP_000542.1(LRG_322p1):p.?,NC_000003.11:g.10191605C>T;NC_000003.11:g.10184641T>C,3;3,10191605;10184641,.;.,C;T,T;C,NC_000003.12:g.10149921C>T;NC_000003.12:g.10142957T>C,3;3,10149921;10142957,.;.,C;T,T;C,VHL;VHL,HGNC:12687;HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA;Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",;
Yes,29891534,598; 340+770,Yes,c.598C>T; c.340+770T>C,NM_000551.3,p.Arg200Trp,R200W(c.598C>T),missense_variant,"F3, II.2",3,No,HP:0001901,"(Lenglet et al., 2018)",E0Y6M,M,,,Patient,NM_000551.3:c.598C>T;NM_000551.3:c.340+770T>C,;,NM_000551.3:c.598C>T;NM_000551.3:c.340+770T>C,;NC_000003.11(NM_000551.3):c.340+770T>C,;NG_008212.3(NM_000551.3):c.340+770T>C,NG_008212.3:g.13287C>T;NG_008212.3:g.6323T>C,LRG_322:g.13287C>T;LRG_322:g.6323T>C,LRG_322t1:c.598C>T;LRG_322t1:c.340+770T>C,NP_000542.1(LRG_322p1):p.(Arg200Trp);NP_000542.1(LRG_322p1):p.?,NC_000003.11:g.10191605C>T;NC_000003.11:g.10184641T>C,3;3,10191605;10184641,.;.,C;T,T;C,NC_000003.12:g.10149921C>T;NC_000003.12:g.10142957T>C,3;3,10149921;10142957,.;.,C;T,T;C,VHL;VHL,HGNC:12687;HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA;Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",;
Yes,29891534,492; 340+574,Yes,c.492G>T; c.340+574A>T,NM_000551.3,p.Gln164His,Q164H(c.492G>T),missense_variant,"F6, II.1",6,No,HP:0001744,"(Lenglet et al., 2018)",E6Y0M,M,,"The authors identify a new VHL cryptic exon (termed E1') deep in intron 1 that is naturally expressed in many tissues. Mutations in E1' are identified in 7 families with erythrocytosis and in 1 large family with typical VHL disease but without any alteration in the other VHL exons. In this study, the authors show that the mutations in E1' induced a dysregulation of VHL splicing with excessive retention of E1' and were associated with a downregulation of VHL protein expression. In F6, II.1, two mutations are found on the VHL gene. c.492G>T results in a missense variant. c.340+574A>T is a mutation in acceptor splice site for codon E1'. The patient was diagnosed with erythrocytosis.",Patient,NM_000551.3:c.492G>T;NM_000551.3:c.340+574A>T,;,NM_000551.3:c.492G>T;NM_000551.3:c.340+574A>T,;NC_000003.11(NM_000551.3):c.340+574A>T,;NG_008212.3(NM_000551.3):c.340+574A>T,NG_008212.3:g.13181G>T;NG_008212.3:g.6127A>T,LRG_322:g.13181G>T;LRG_322:g.6127A>T,LRG_322t1:c.492G>T;LRG_322t1:c.340+574A>T,NP_000542.1(LRG_322p1):p.(Gln164His);NP_000542.1(LRG_322p1):p.?,NC_000003.11:g.10191499G>T;NC_000003.11:g.10184445A>T,3;3,10191499;10184445,.;.,G;A,T;T,NC_000003.12:g.10149815G>T;NC_000003.12:g.10142761A>T,3;3,10149815;10142761,.;.,G;A,T;T,VHL;VHL,HGNC:12687;HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA;Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",;
Yes,29891534,340+816,Yes,c.340+816A>C,NM_000551.3,Unknown,c.340+816A>C,Unknown,F7,7,No,HP:0001901,"(Lenglet et al., 2018)",E7Y0M,M,,"The authors identify a new VHL cryptic exon (termed E1') deep in intron 1 that is naturally expressed in many tissues. Mutations in E1' are identified in 7 families with erythrocytosis and in 1 large family with typical VHL disease but without any alteration in the other VHL exons. In this study, the authors show that the mutations in E1' induced a dysregulation of VHL splicing with excessive retention of E1' and were associated with a downregulation of VHL protein expression. In F7, homozygous c.340+816A>C mutation in E1' was identified. The patient was diagnosed with erythrocytosis.",Patient,NM_000551.3:c.340+816A>C,,NM_000551.3:c.340+816A>C,NC_000003.11(NM_000551.3):c.340+816A>C,NG_008212.3(NM_000551.3):c.340+816A>C,NG_008212.3:g.6369A>C,LRG_322:g.6369A>C,LRG_322t1:c.340+816A>C,NP_000542.1(LRG_322p1):p.?,NC_000003.11:g.10184687A>C,3,10184687,.,A,C,NC_000003.12:g.10143003A>C,3,10143003,.,A,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29891534,340+617; 340+648,Yes,c.340+617C>G; c.340+648T>C,NM_000551.3,Unknown,c.340+617C>G;c.340+648T>C,Unknown,"F8, I.2",8,No,HP:0009711; HP:0005584; HP:0002666,"(Lenglet et al., 2018)",E15Y0M,M,,"The authors identify a new VHL cryptic exon (termed E1') deep in intron 1 that is naturally expressed in many tissues. Mutations in E1' are identified in 7 families with erythrocytosis and in 1 large family with typical VHL disease but without any alteration in the other VHL exons. In this study, the authors show that the mutations in E1' induced a dysregulation of VHL splicing with excessive retention of E1' and were associated with a downregulation of VHL protein expression. In F8, c.340+617C>G and c.340+648T>C mutations on the same allele result in p.Leu128Val + p.Leu138Pro mutations on potential X1 protein encoded by E1' exon. The family display VHL disease phenotypes of retinal capillary hemangioma, renall cell carcinoma, pheochromocytoma and CNS hemangioblastoma. ACMG: 'PP1' because 6 confirmed carriers of the mutation in the family were all affeccted by VHL disease; 'PP4' because the patients' phenotypes and family history are highly specidic for a disease with single genetic etiology.",Patient,NM_000551.3:c.340+617C>G;NM_000551.3:c.340+648T>C,;,NM_000551.3:c.340+617C>G;NM_000551.3:c.340+648T>C,NC_000003.11(NM_000551.3):c.340+617C>G;NC_000003.11(NM_000551.3):c.340+648T>C,NG_008212.3(NM_000551.3):c.340+617C>G;NG_008212.3(NM_000551.3):c.340+648T>C,NG_008212.3:g.6170C>G;NG_008212.3:g.6201T>C,LRG_322:g.6170C>G;LRG_322:g.6201T>C,LRG_322t1:c.340+617C>G;LRG_322t1:c.340+648T>C,NP_000542.1(LRG_322p1):p.?;NP_000542.1(LRG_322p1):p.?,NC_000003.11:g.10184488C>G;NC_000003.11:g.10184519T>C,3;3,10184488;10184519,.;.,C;T,G;C,NC_000003.12:g.10142804C>G;NC_000003.12:g.10142835T>C,3;3,10142804;10142835,.;.,C;T,G;C,VHL;VHL,HGNC:12687;HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA;Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",;
Yes,29891534,340+617; 340+648,Yes,c.340+617C>G; c.340+648T>C,NM_000551.3,Unknown,c.340+617C>G;c.340+648T>C,Unknown,"F8, I.3",8,No,HP:0002666; HP:0010797,"(Lenglet et al., 2018)",E24Y0M,M,,,Patient,NM_000551.3:c.340+617C>G;NM_000551.3:c.340+648T>C,;,NM_000551.3:c.340+617C>G;NM_000551.3:c.340+648T>C,NC_000003.11(NM_000551.3):c.340+617C>G;NC_000003.11(NM_000551.3):c.340+648T>C,NG_008212.3(NM_000551.3):c.340+617C>G;NG_008212.3(NM_000551.3):c.340+648T>C,NG_008212.3:g.6170C>G;NG_008212.3:g.6201T>C,LRG_322:g.6170C>G;LRG_322:g.6201T>C,LRG_322t1:c.340+617C>G;LRG_322t1:c.340+648T>C,NP_000542.1(LRG_322p1):p.?;NP_000542.1(LRG_322p1):p.?,NC_000003.11:g.10184488C>G;NC_000003.11:g.10184519T>C,3;3,10184488;10184519,.;.,C;T,G;C,NC_000003.12:g.10142804C>G;NC_000003.12:g.10142835T>C,3;3,10142804;10142835,.;.,C;T,G;C,VHL;VHL,HGNC:12687;HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA;Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",;
Yes,29891534,340+617; 340+648,Yes,c.340+617C>G; c.340+648T>C,NM_000551.3,Unknown,c.340+617C>G;c.340+648T>C,Unknown,"F8, II.1",8,No,HP:0002666; HP:0010797,"(Lenglet et al., 2018)",E24Y0M,M,,,Patient,NM_000551.3:c.340+617C>G;NM_000551.3:c.340+648T>C,;,NM_000551.3:c.340+617C>G;NM_000551.3:c.340+648T>C,NC_000003.11(NM_000551.3):c.340+617C>G;NC_000003.11(NM_000551.3):c.340+648T>C,NG_008212.3(NM_000551.3):c.340+617C>G;NG_008212.3(NM_000551.3):c.340+648T>C,NG_008212.3:g.6170C>G;NG_008212.3:g.6201T>C,LRG_322:g.6170C>G;LRG_322:g.6201T>C,LRG_322t1:c.340+617C>G;LRG_322t1:c.340+648T>C,NP_000542.1(LRG_322p1):p.?;NP_000542.1(LRG_322p1):p.?,NC_000003.11:g.10184488C>G;NC_000003.11:g.10184519T>C,3;3,10184488;10184519,.;.,C;T,G;C,NC_000003.12:g.10142804C>G;NC_000003.12:g.10142835T>C,3;3,10142804;10142835,.;.,C;T,G;C,VHL;VHL,HGNC:12687;HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA;Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",;
Yes,29891534,340+617; 340+648,Yes,c.340+617C>G; c.340+648T>C,NM_000551.3,Unknown,c.340+617C>G;c.340+648T>C,Unknown,"F8, II.2",8,No,HP:0009711,"(Lenglet et al., 2018)",E22Y0M,M,,,Patient,NM_000551.3:c.340+617C>G;NM_000551.3:c.340+648T>C,;,NM_000551.3:c.340+617C>G;NM_000551.3:c.340+648T>C,NC_000003.11(NM_000551.3):c.340+617C>G;NC_000003.11(NM_000551.3):c.340+648T>C,NG_008212.3(NM_000551.3):c.340+617C>G;NG_008212.3(NM_000551.3):c.340+648T>C,NG_008212.3:g.6170C>G;NG_008212.3:g.6201T>C,LRG_322:g.6170C>G;LRG_322:g.6201T>C,LRG_322t1:c.340+617C>G;LRG_322t1:c.340+648T>C,NP_000542.1(LRG_322p1):p.?;NP_000542.1(LRG_322p1):p.?,NC_000003.11:g.10184488C>G;NC_000003.11:g.10184519T>C,3;3,10184488;10184519,.;.,C;T,G;C,NC_000003.12:g.10142804C>G;NC_000003.12:g.10142835T>C,3;3,10142804;10142835,.;.,C;T,G;C,VHL;VHL,HGNC:12687;HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA;Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",;
Yes,29891534,340+617; 340+648,Yes,c.340+617C>G; c.340+648T>C,NM_000551.3,Unknown,c.340+617C>G;c.340+648T>C,Unknown,"F8, II. 6",8,No,HP:0009711,"(Lenglet et al., 2018)",E16Y0M,F,,,Patient,NM_000551.3:c.340+617C>G;NM_000551.3:c.340+648T>C,;,NM_000551.3:c.340+617C>G;NM_000551.3:c.340+648T>C,NC_000003.11(NM_000551.3):c.340+617C>G;NC_000003.11(NM_000551.3):c.340+648T>C,NG_008212.3(NM_000551.3):c.340+617C>G;NG_008212.3(NM_000551.3):c.340+648T>C,NG_008212.3:g.6170C>G;NG_008212.3:g.6201T>C,LRG_322:g.6170C>G;LRG_322:g.6201T>C,LRG_322t1:c.340+617C>G;LRG_322t1:c.340+648T>C,NP_000542.1(LRG_322p1):p.?;NP_000542.1(LRG_322p1):p.?,NC_000003.11:g.10184488C>G;NC_000003.11:g.10184519T>C,3;3,10184488;10184519,.;.,C;T,G;C,NC_000003.12:g.10142804C>G;NC_000003.12:g.10142835T>C,3;3,10142804;10142835,.;.,C;T,G;C,VHL;VHL,HGNC:12687;HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA;Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",;
Yes,29891534,340+617; 340+648,Yes,c.340+617C>G; c.340+648T>C,NM_000551.3,Unknown,c.340+617C>G;c.340+648T>C,Unknown,"F8, II.7",8,No,HP:0009711,"(Lenglet et al., 2018)",E10Y0M,M,,,Patient,NM_000551.3:c.340+617C>G;NM_000551.3:c.340+648T>C,;,NM_000551.3:c.340+617C>G;NM_000551.3:c.340+648T>C,NC_000003.11(NM_000551.3):c.340+617C>G;NC_000003.11(NM_000551.3):c.340+648T>C,NG_008212.3(NM_000551.3):c.340+617C>G;NG_008212.3(NM_000551.3):c.340+648T>C,NG_008212.3:g.6170C>G;NG_008212.3:g.6201T>C,LRG_322:g.6170C>G;LRG_322:g.6201T>C,LRG_322t1:c.340+617C>G;LRG_322t1:c.340+648T>C,NP_000542.1(LRG_322p1):p.?;NP_000542.1(LRG_322p1):p.?,NC_000003.11:g.10184488C>G;NC_000003.11:g.10184519T>C,3;3,10184488;10184519,.;.,C;T,G;C,NC_000003.12:g.10142804C>G;NC_000003.12:g.10142835T>C,3;3,10142804;10142835,.;.,C;T,G;C,VHL;VHL,HGNC:12687;HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA;Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",;
Yes,29891534,429,Yes,c.429C>T,NM_000551.3,p.Asp143Asp,D143D(c.429C>T),synonymous_variant,"F9, II.1",9,No,HP:0001901,"(Lenglet et al., 2018)",E0Y5M,M,,"The authos demonstrate a pathogenic role for synonymous mutations in VHL exon 2 that altered splicing through E2-skipping in 5 families with erythrocytosis or VHL disease. In F9 and F10, homozygous D143D(c.429C>T) mutations were detected. F9, II.1 and F10, II.1 were both diagnosed with erythrocytosis. F9, II.1 also has Hb sitia mutation. F10, II. 1 also has beta thalassemia mutation and experience splenomegaly.",Patient,NM_000551.3:c.429C>T,,NM_000551.3:c.429C>T,,,NG_008212.3:g.9968C>T,LRG_322:g.9968C>T,LRG_322t1:c.429C>T,NP_000542.1(LRG_322p1):p.(Asp143=),NC_000003.11:g.10188286C>T,3,10188286,.,C,T,NC_000003.12:g.10146602C>T,3,10146602,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29891534,429,Yes,c.429C>T,NM_000551.3,p.Asp143Asp,D143D(c.429C>T),synonymous_variant,"F10, II.1",10,No,HP:0001901,"(Lenglet et al., 2018)",E4Y6M,F,,,Patient,NM_000551.3:c.429C>T,,NM_000551.3:c.429C>T,,,NG_008212.3:g.9968C>T,LRG_322:g.9968C>T,LRG_322t1:c.429C>T,NP_000542.1(LRG_322p1):p.(Asp143=),NC_000003.11:g.10188286C>T,3,10188286,.,C,T,NC_000003.12:g.10146602C>T,3,10146602,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29891534,414,No,c.414A>G,NM_000551.3,p.Pro138Pro,P138P(c.414A>G),synonymous_variant,"F11, I.1",11,No,HP:0002668; HP:0002666; HP:0010797; HP:0005584,"(Lenglet et al., 2018)",Unknown,Unknown,,"The authos demonstrate a pathogenic role for synonymous mutations in VHL exon 2 that altered splicing through E2-skipping in 5 families with erythrocytosis or VHL disease. In F11 and F12, heterozygous P138P(c.414A>G)/WT mutations was detected. Both families display VHL disease phenotypes. F11, I.1 was diagnosed with paraganglioma, pheochromocytoma, hemangioblastoma and renal cell carcinoma. F11, II.2 was diagnosed with pheochromocytoma and hemangioblastoma. F11, III.1 and 3 members of F12 were diagnosed with pheochromocytoma. ACMG: 'PP1' because 3 confirmed carriers of the mutation in F11 were all affeccted by VHL disease, and 4 confirmed carriers of the mutation in F12 were all affeccted by VHL disease; 'PP4' because the patients' phenotypes and family history are highly specidic for a disease with single genetic etiology.",Patient,NM_000551.3:c.414A>G,,NM_000551.3:c.414A>G,,,NG_008212.3:g.9953A>G,LRG_322:g.9953A>G,LRG_322t1:c.414A>G,NP_000542.1(LRG_322p1):p.(Pro138=),NC_000003.11:g.10188271A>G,3,10188271,.,A,G,NC_000003.12:g.10146587A>G,3,10146587,.,A,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29891534,414,No,c.414A>G,NM_000551.3,p.Pro138Pro,P138P(c.414A>G),synonymous_variant,"F11, II.2",11,No,HP:0002666; HP:0010797,"(Lenglet et al., 2018)",Unknown,Unknown,,,Patient,NM_000551.3:c.414A>G,,NM_000551.3:c.414A>G,,,NG_008212.3:g.9953A>G,LRG_322:g.9953A>G,LRG_322t1:c.414A>G,NP_000542.1(LRG_322p1):p.(Pro138=),NC_000003.11:g.10188271A>G,3,10188271,.,A,G,NC_000003.12:g.10146587A>G,3,10146587,.,A,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29891534,414,No,c.414A>G,NM_000551.3,p.Pro138Pro,P138P(c.414A>G),synonymous_variant,"F11, III.1",11,No,HP:0002666,"(Lenglet et al., 2018)",Unknown,Unknown,,,Patient,NM_000551.3:c.414A>G,,NM_000551.3:c.414A>G,,,NG_008212.3:g.9953A>G,LRG_322:g.9953A>G,LRG_322t1:c.414A>G,NP_000542.1(LRG_322p1):p.(Pro138=),NC_000003.11:g.10188271A>G,3,10188271,.,A,G,NC_000003.12:g.10146587A>G,3,10146587,.,A,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29891534,414,No,c.414A>G,NM_000551.3,p.Pro138Pro,P138P(c.414A>G),synonymous_variant,F12,12,No,HP:0002666,"(Lenglet et al., 2018)",Unknown,Unknown,,,Patient,NM_000551.3:c.414A>G,,NM_000551.3:c.414A>G,,,NG_008212.3:g.9953A>G,LRG_322:g.9953A>G,LRG_322t1:c.414A>G,NP_000542.1(LRG_322p1):p.(Pro138=),NC_000003.11:g.10188271A>G,3,10188271,.,A,G,NC_000003.12:g.10146587A>G,3,10146587,.,A,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29891534,414,No,c.414A>G,NM_000551.3,p.Pro138Pro,P138P(c.414A>G),synonymous_variant,F12,12,No,HP:0002666,"(Lenglet et al., 2018)",Unknown,Unknown,,,Patient,NM_000551.3:c.414A>G,,NM_000551.3:c.414A>G,,,NG_008212.3:g.9953A>G,LRG_322:g.9953A>G,LRG_322t1:c.414A>G,NP_000542.1(LRG_322p1):p.(Pro138=),NC_000003.11:g.10188271A>G,3,10188271,.,A,G,NC_000003.12:g.10146587A>G,3,10146587,.,A,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29891534,414,No,c.414A>G,NM_000551.3,p.Pro138Pro,P138P(c.414A>G),synonymous_variant,F12,12,No,HP:0002666,"(Lenglet et al., 2018)",Unknown,Unknown,,,Patient,NM_000551.3:c.414A>G,,NM_000551.3:c.414A>G,,,NG_008212.3:g.9953A>G,LRG_322:g.9953A>G,LRG_322t1:c.414A>G,NP_000542.1(LRG_322p1):p.(Pro138=),NC_000003.11:g.10188271A>G,3,10188271,.,A,G,NC_000003.12:g.10146587A>G,3,10146587,.,A,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29891534,414,No,c.414A>G,NM_000551.3,p.Pro138Pro,P138P(c.414A>G),synonymous_variant,F12,12,No,HP:0002666,"(Lenglet et al., 2018)",Unknown,Unknown,,,Patient,NM_000551.3:c.414A>G,,NM_000551.3:c.414A>G,,,NG_008212.3:g.9953A>G,LRG_322:g.9953A>G,LRG_322t1:c.414A>G,NP_000542.1(LRG_322p1):p.(Pro138=),NC_000003.11:g.10188271A>G,3,10188271,.,A,G,NC_000003.12:g.10146587A>G,3,10146587,.,A,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29891534,598; 340+694,Yes,c.598C>T; c.340+694_711dup,NM_000551.3,p.Arg200Trp; unknown,R200W(c.598C>T),missense_variant,"F4, II.1",4,No,"HP:0001901; HP:0002625, HP:0001342","(Lenglet et al., 2018)",E7Y0M,M,,"The authors identify a new VHL cryptic exon (termed E1') deep in intron 1 that is naturally expressed in many tissues. Mutations in E1' are identified in 7 families with erythrocytosis and in 1 large family with typical VHL disease but without any alteration in the other VHL exons. In this study, the authors show that the mutations in E1' induced a dysregulation of VHL splicing with excessive retention of E1' and were associated with a downregulation of VHL protein expression. In F4, II.1, two mutations are found on the VHL gene. c.598C>T results in a missense variant. c.340+694_711dup p.Trp159X? mutation on potential X1 protein encoded by E1' exon. Patient also has FV leiden mutation. The patient was diagnosed with erythrocytosis and also experienced deep vein thrombosis and intracerebral hemorrhage.",Patient,NM_000551.3:c.598C>T;NM_000551.3:c.340+694_711dup,;Required information for NM_000551.3 is missing from the Universal Transcript Archive|Query gene2transcripts with search term NM_000551 for available transcripts,NM_000551.3:c.598C>T;,;,;,NG_008212.3:g.13287C>T;,LRG_322:g.13287C>T;,LRG_322t1:c.598C>T;,NP_000542.1(LRG_322p1):p.(Arg200Trp);,NC_000003.11:g.10191605C>T;,3;,10191605;,.;,C;,T;,NC_000003.12:g.10149921C>T;,3;,10149921;,.;,C;,T;,VHL;,HGNC:12687;,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA;",;
Yes,29891534,430; 340+694,Yes,c.430G>A; c.340+694_711dup,NM_000551.3,p.Gly144Arg; unknown,G144R(c.430G>A),missense_variant,"F5, II.2",5,No,HP:0001901,"(Lenglet et al., 2018)",E13Y0M,M,,"The authors identify a new VHL cryptic exon (termed E1') deep in intron 1 that is naturally expressed in many tissues. Mutations in E1' are identified in 7 families with erythrocytosis and in 1 large family with typical VHL disease but without any alteration in the other VHL exons. In this study, the authors show that the mutations in E1' induced a dysregulation of VHL splicing with excessive retention of E1' and were associated with a downregulation of VHL protein expression. In F5, II.2, two mutations are found on the VHL gene. c.430G>A results in a missense variant. c.340+694_711dup p.Trp159X? mutation on potential X1 protein encoded by E1' exon.The patient was diagnosed with erythrocytosis.",Patient,NM_000551.3:c.430G>A;NM_000551.3:c.340+694_711dup,;Required information for NM_000551.3 is missing from the Universal Transcript Archive|Query gene2transcripts with search term NM_000551 for available transcripts,NM_000551.3:c.430G>A;,;,;,NG_008212.3:g.9969G>A;,LRG_322:g.9969G>A;,LRG_322t1:c.430G>A;,NP_000542.1(LRG_322p1):p.(Gly144Arg);,NC_000003.11:g.10188287G>A;,3;,10188287;,.;,G;,A;,NC_000003.12:g.10146603G>A;,3;,10146603;,.;,G;,A;,VHL;,HGNC:12687;,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA;",;
Yes,11850829,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,1,1,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient I","36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. The study identified selective loss of chromosome 11 in pheochromocytomas associated with VHL. Patient I to XV with VHL-associated pheochromocytoma come from the large, multi-generationed, Black Forest VHL family (c.292T>C) of Germany (reported in Brauch et al., 1995) with missence mutation (c.292T>C) in the VHL gene. ACMG evidence codes:  'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,1,1,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient II",,Tumour,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,1,1,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient III",,Tumour,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,1,1,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient IV, 3 PCC tumor samples",,Tumour,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,1,1,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient V",,Tumour,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,1,1,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient VI",,Tumour,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,1,1,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient VII, 3 PCC tumor samples",,Tumour,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,1,1,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient VII",,Tumour,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,1,1,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient IX",,Tumour,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,1,1,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient X, 5 PCC tumor samples",,Tumour,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,1,1,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient XI",,Tumour,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,1,1,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient XII",,Tumour,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,1,1,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient XIII",,Tumour,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,1,1,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient XIV, 2 PCC tumor samples",,Tumour,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H (c.292T>C),missense_variant,1,1,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient XV, 4 PCC tumor samples",,Tumour,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,562,No,c.562C>G,NM_000551.3,p.Leu188Val,L188V(c.562C>G),missense_variant,N/A,Unknown,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient XVI","36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. The study identified selective loss of chromosome 11 in pheochromocytomas associated with VHL.  Patient XVI, XX and XXI in VHL-associated pheochromocytoma were found with germline missense mutation (c.562C>G) in the VHL gene. ACMG evidence codes:  'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:c.562C>G,,NM_000551.3:c.562C>G,,,NG_008212.3:g.13251C>G,LRG_322:g.13251C>G,LRG_322t1:c.562C>G,NP_000542.1(LRG_322p1):p.(Leu188Val),NC_000003.11:g.10191569C>G,3,10191569,.,C,G,NC_000003.12:g.10149885C>G,3,10149885,.,C,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,562,No,c.562C>G,NM_000551.3,p.Leu188Val,L188V(c.562C>G),missense_variant,N/A,Unknown,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient XX, 2 PCC tumor samples",,Tumour,NM_000551.3:c.562C>G,,NM_000551.3:c.562C>G,,,NG_008212.3:g.13251C>G,LRG_322:g.13251C>G,LRG_322t1:c.562C>G,NP_000542.1(LRG_322p1):p.(Leu188Val),NC_000003.11:g.10191569C>G,3,10191569,.,C,G,NC_000003.12:g.10149885C>G,3,10149885,.,C,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,562,No,c.562C>G,NM_000551.3,p.Leu188Val,L188V(c.562C>G),missense_variant,N/A,Unknown,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient XXI",,Tumour,NM_000551.3:c.562C>G,,NM_000551.3:c.562C>G,,,NG_008212.3:g.13251C>G,LRG_322:g.13251C>G,LRG_322t1:c.562C>G,NP_000542.1(LRG_322p1):p.(Leu188Val),NC_000003.11:g.10191569C>G,3,10191569,.,C,G,NC_000003.12:g.10149885C>G,3,10149885,.,C,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,533,No,c.533T>A,NM_000551.3,p.Leu178Gln,L178Q (c.533T>A),missense_variant,N/A,Unknown,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient XVII",36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. The study identified selective loss of chromosome 11 in pheochromocytomas associated with VHL. Patient XVII and XVIII in VHL-associated pheochromocytoma were found with germline missense mutation (c.533T>A) in the VHL gene.   ACMG evidence codes:  'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.,Tumour,NM_000551.3:c.533T>A,,NM_000551.3:c.533T>A,,,NG_008212.3:g.13222T>A,LRG_322:g.13222T>A,LRG_322t1:c.533T>A,NP_000542.1(LRG_322p1):p.(Leu178Gln),NC_000003.11:g.10191540T>A,3,10191540,.,T,A,NC_000003.12:g.10149856T>A,3,10149856,.,T,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,533,No,c.533T>A,NM_000551.3,p.Leu178Gln,L178Q (c.533T>A),missense_variant,N/A,Unknown,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient XVIII, 3 PCC tumor samples",,Tumour,NM_000551.3:c.533T>A,,NM_000551.3:c.533T>A,,,NG_008212.3:g.13222T>A,LRG_322:g.13222T>A,LRG_322t1:c.533T>A,NP_000542.1(LRG_322p1):p.(Leu178Gln),NC_000003.11:g.10191540T>A,3,10191540,.,T,A,NC_000003.12:g.10149856T>A,3,10149856,.,T,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,482,No,c.482G>A,NM_000551.3,p.Arg161Gln,R161Q (c.482G>A),missense_variant,N/A,Unknown,No,HP:0002666,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated PCC, Patient XIX",36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. The study identified selective loss of chromosome 11 in pheochromocytomas associated with VHL. Patient XIIX in VHL-associated pheochromocytoma were found with germline missense mutation (c.482G>A) in the VHL gene. ACMG evidence codes:  'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.,Tumour,NM_000551.3:c.482G>A,,NM_000551.3:c.482G>A,,,NG_008212.3:g.13171G>A,LRG_322:g.13171G>A,LRG_322t1:c.482G>A,NP_000542.1(LRG_322p1):p.(Arg161Gln),NC_000003.11:g.10191489G>A,3,10191489,.,G,A,NC_000003.12:g.10149805G>A,3,10149805,.,G,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,233,No,c.233A>G,NM_000551.3,p.Asn78Ser,N78S (c.233A>G),missense_variant,N/A,Unknown,No,HP:0010797,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated hemangioblastoma, Patient II, 2 hemangioblastoma samples",36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. Patient II in VHL-Associated hemangioblastoma was found with germline missense mutation (c.233A>G) in the VHL gene. ACMG evidence codes:  'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.,Tumour,NM_000551.3:c.233A>G,,NM_000551.3:c.233A>G,,,NG_008212.3:g.5446A>G,LRG_322:g.5446A>G,LRG_322t1:c.233A>G,NP_000542.1(LRG_322p1):p.(Asn78Ser),NC_000003.11:g.10183764A>G,3,10183764,.,A,G,NC_000003.12:g.10142080A>G,3,10142080,.,A,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,Unknown,No,2kb del,NM_000551.3,Unknown,Unknown,deletion,N/A,Unknown,No,HP:0010797,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated hemangioblastoma, Patient V,  2 hemangioblastoma samples",36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances.  Patient V with VHL-Associated hemangioblastoma was found with 2kB germline deletion in the VHL gene.  Patient VI with VHL-Associated hemangioblastoma was found to have large germline deletion of unknown length in the VHL gene. ACMG evidence codes:  'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.,Tumour,NM_000551.3:2kb,NM_000551.3:c.2kb: char 18: end of input,,,,,,,,,,,,,,,,,,,,,,,
Yes,11850829,Unknown,No,?kb del,NM_000551.3,Unknown,Unknown,deletion,N/A,Unknown,No,HP:0010797,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated hemangioblastoma, Patient VI",,Tumour,NM_000551.3:?kb,"NM_000551.3:c.?kb: char 14: expected one of (, *, or a digit",,,,,,,,,,,,,,,,,,,,,,,
Yes,11850829,486,No,c.486C>G,NM_000551.3,p.Cys162Trp,C162W (c.486C>G),missense_variant,N/A,Unknown,No,HP:0010797,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated hemangioblastoma, Patient IV",36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances.  Patient IV in VHL-Associated hemangioblastoma was found with germline missense mutation (c.486C>G) in the VHL gene. ACMG evidence codes:  'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.,Tumour,NM_000551.3:c.486C>G,,NM_000551.3:c.486C>G,,,NG_008212.3:g.13175C>G,LRG_322:g.13175C>G,LRG_322t1:c.486C>G,NP_000542.1(LRG_322p1):p.(Cys162Trp),NC_000003.11:g.10191493C>G,3,10191493,.,C,G,NC_000003.12:g.10149809C>G,3,10149809,.,C,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850829,230,No,c.230_231insTCT,NM_000551.3,p.Cys77_Asn78insLeu,C77_N78insL (c.230insTCT),inframe_insertion,N/A,Unknown,No,HP:0010797,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated hemangioblastoma, Patient III,  2 hemangioblastoma samples",36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances.  Patient III in VHL-Associated hemangioblastoma was found with germline insertion mutation (c.230insTCT) in the VHL gene. ACMG evidence codes:  'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.,Tumour,NM_000551.3:c.230_231insTCT,,NM_000551.3:c.230_231insTCT,,,NG_008212.3:g.5443_5444insTCT,LRG_322:g.5443_5444insTCT,LRG_322t1:c.230_231insTCT,NP_000542.1(LRG_322p1):p.(Cys77_Asn78insLeu),NC_000003.11:g.10183761_10183762insTCT,3,10183761,.,G,GTCT,NC_000003.12:g.10142077_10142078insTCT,3,10142077,.,G,GTCT,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,10627136,203,No,c.203C>G,NM_000551.3,p.Ser68Trp,S68W(c.203C>G),missense_variant,II2,1,No,HP:0002666,"(Martin et al., 1997)",lk24Y0M,F,,"This study presented a family with S68W (c.203C>G) mutation in VHL gene with variable penetrance. The mutation was identified in 5 family members. II:2 had her pheochromocytoma removed at age 24. By contrastsib II:4 has remained asymptomatic and is presently 63 years of age. Of II:2's three children, two carrythe S68W mutation. III:2 presented with symptoms of pheochromocytoma at age 12, whilst III:1 at age35 has remained asymptomatic. III:1's only endocrine problem was thyroiditis at age 24. Of II:4's six children, four have been tested to date. III:4 carries the S68W mutation and was diagnosed with pheochromocytoma at the age of 23. None of the untested sibs have presented with symptoms of pheochromocytoma and carrier individuals have not had any other clinical features or endocrine abnormalities to suggest an associated genetic syndromic disorder. In addition, clinical monitoring of the individuals carrying the S68W mutation, which includes ophthalmological examinations, has not revealed symptoms indicative of VHL or any other genetic syndromic disorders. ACMG: 'PP1' because 3 out of 5 confirmed carriers of the mutation in the family were affected by pheochromocytoma and the asymptomatic carriers are 63Y and 35Y respectively; 'PP4' because the patients' phenotypes and family history are highly specidic for a disease with single genetic etiology.",Patient,NM_000551.3:c.203C>G,,NM_000551.3:c.203C>G,,,NG_008212.3:g.5416C>G,LRG_322:g.5416C>G,LRG_322t1:c.203C>G,NP_000542.1(LRG_322p1):p.(Ser68Trp),NC_000003.11:g.10183734C>G,3,10183734,.,C,G,NC_000003.12:g.10142050C>G,3,10142050,.,C,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,10627136,203,No,c.203C>G,NM_000551.3,p.Ser68Trp,S68W(c.203C>G),missense_variant,II4,1,No,none,"(Martin et al., 1997)",lk63Y0M,F,,,Patient,NM_000551.3:c.203C>G,,NM_000551.3:c.203C>G,,,NG_008212.3:g.5416C>G,LRG_322:g.5416C>G,LRG_322t1:c.203C>G,NP_000542.1(LRG_322p1):p.(Ser68Trp),NC_000003.11:g.10183734C>G,3,10183734,.,C,G,NC_000003.12:g.10142050C>G,3,10142050,.,C,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,10627136,203,No,c.203C>G,NM_000551.3,p.Ser68Trp,S68W(c.203C>G),missense_variant,III2,1,No,HP:0002666,"(Martin et al., 1997)",lk12Y0M,F,,,Patient,NM_000551.3:c.203C>G,,NM_000551.3:c.203C>G,,,NG_008212.3:g.5416C>G,LRG_322:g.5416C>G,LRG_322t1:c.203C>G,NP_000542.1(LRG_322p1):p.(Ser68Trp),NC_000003.11:g.10183734C>G,3,10183734,.,C,G,NC_000003.12:g.10142050C>G,3,10142050,.,C,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,10627136,203,No,c.203C>G,NM_000551.3,p.Ser68Trp,S68W(c.203C>G),missense_variant,III1,1,No,none,"(Martin et al., 1997)",lk35Y0M,F,,,Patient,NM_000551.3:c.203C>G,,NM_000551.3:c.203C>G,,,NG_008212.3:g.5416C>G,LRG_322:g.5416C>G,LRG_322t1:c.203C>G,NP_000542.1(LRG_322p1):p.(Ser68Trp),NC_000003.11:g.10183734C>G,3,10183734,.,C,G,NC_000003.12:g.10142050C>G,3,10142050,.,C,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,10627136,203,No,c.203C>G,NM_000551.3,p.Ser68Trp,S68W(c.203C>G),missense_variant,III4,1,No,HP:0002666,"(Martin et al., 1997)",lk23Y0M,M,,,Patient,NM_000551.3:c.203C>G,,NM_000551.3:c.203C>G,,,NG_008212.3:g.5416C>G,LRG_322:g.5416C>G,LRG_322t1:c.203C>G,NP_000542.1(LRG_322p1):p.(Ser68Trp),NC_000003.11:g.10183734C>G,3,10183734,.,C,G,NC_000003.12:g.10142050C>G,3,10142050,.,C,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,18475055,509,No,c.509T>G,NM_000551.3,p.Val170Gly,V170G(c.509T>G),missense_variant,1,1,No,HP:0030405; HP:0002666,"(Pulcrano et al., 2008)",lk30Y0M,F,proband; patient 1,"Four patients from the same family carrying missense VHL mutation c.509 T>G were screened for VHL related lesions. Patient 1, 30Y F, had undergone treatment for pancreatic endocrine tumors and pheochromocytoma. Patient 2, 30Y M, was affected by retinal angioma, was asymptomatic for bilateral adrenal pheochromocytoma and sacral, intercarotid paraganglioma. Patient 3 underwent treatment for pheochromocytoma. Investigations revealed additional pancreatic endocrine tumor and a pheochromocytoma. Patient 4 had an endocrine pancreatic tumor and a pheochromocytoma. ACMG: 'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology.",Patient,NM_000551.3:c.509T>G,,NM_000551.3:c.509T>G,,,NG_008212.3:g.13198T>G,LRG_322:g.13198T>G,LRG_322t1:c.509T>G,NP_000542.1(LRG_322p1):p.(Val170Gly),NC_000003.11:g.10191516T>G,3,10191516,.,T,G,NC_000003.12:g.10149832T>G,3,10149832,.,T,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,18475055,509,No,c.509T>G,NM_000551.3,p.Val170Gly,V170G(c.509T>G),missense_variant,1,1,No,HP:0009711; HP:0002666; HP:0002668,"(Pulcrano et al., 2008)",lk30Y0M,M,patient 2,,Patient,NM_000551.3:c.509T>G,,NM_000551.3:c.509T>G,,,NG_008212.3:g.13198T>G,LRG_322:g.13198T>G,LRG_322t1:c.509T>G,NP_000542.1(LRG_322p1):p.(Val170Gly),NC_000003.11:g.10191516T>G,3,10191516,.,T,G,NC_000003.12:g.10149832T>G,3,10149832,.,T,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,18475055,509,No,c.509T>G,NM_000551.3,p.Val170Gly,V170G(c.509T>G),missense_variant,1,1,No,HP:0002666; HP:0030405,"(Pulcrano et al., 2008)",lk38Y0M,F,patient 3,,Patient,NM_000551.3:c.509T>G,,NM_000551.3:c.509T>G,,,NG_008212.3:g.13198T>G,LRG_322:g.13198T>G,LRG_322t1:c.509T>G,NP_000542.1(LRG_322p1):p.(Val170Gly),NC_000003.11:g.10191516T>G,3,10191516,.,T,G,NC_000003.12:g.10149832T>G,3,10149832,.,T,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,18475055,509,No,c.509T>G,NM_000551.3,p.Val170Gly,V170G(c.509T>G),missense_variant,1,1,No,HP:0002666; HP:0030405,"(Pulcrano et al., 2008)",lk31Y0M,M,patient 4,,Patient,NM_000551.3:c.509T>G,,NM_000551.3:c.509T>G,,,NG_008212.3:g.13198T>G,LRG_322:g.13198T>G,LRG_322t1:c.509T>G,NP_000542.1(LRG_322p1):p.(Val170Gly),NC_000003.11:g.10191516T>G,3,10191516,.,T,G,NC_000003.12:g.10149832T>G,3,10149832,.,T,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,Unknown,No,Unknown,NM_000551.3,p.F76del,p.F76del,inframe_deletion,1,1,No,HP:0010797; HP:0000107; HP:0001737,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,17 families (n=109 individuals) were tested  for VHL mutations. Mutation analysis was performed by direct sequencing of the VHL gene. Mutations were identified in 36 patients. Mutations-carriers were screened for VHL disease-related tumors and were offered follow-up annual examinations. Tumor status and phenotypes were documented at initial screening and at follow ups. 4 (3 adults and 1 children) members from family 1 were tested positive with p.F76del mutation. 3 adult patients were affected at initial screening. 1 children were asymptomatic both at initial screening and at last follow up. ACMG evidence codes:  'PP4' because the patients' family history are highly specific for a disease with single genetic etiology.,Patient,NM_000551.3:Unknown,"NM_000551.3:c.Unknown: char 14: expected one of (, *, or a digit",,,,,,,,,,,,,,,,,,,,,,,
Yes,20064270,Unknown,No,Unknown,NM_000551.3,p.F76del,p.F76del,inframe_deletion,1,1,No,HP:0010797,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,,Patient,NM_000551.3:Unknown,"NM_000551.3:c.Unknown: char 14: expected one of (, *, or a digit",,,,,,,,,,,,,,,,,,,,,,,
Yes,20064270,Unknown,No,Unknown,NM_000551.3,p.F76del,p.F76del,inframe_deletion,1,1,No,HP:0010797,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,,Patient,NM_000551.3:Unknown,"NM_000551.3:c.Unknown: char 14: expected one of (, *, or a digit",,,,,,,,,,,,,,,,,,,,,,,
Yes,20064270,Unknown,No,Unknown,NM_000551.3,p.F76del,p.F76del,inframe_deletion,1,1,No,none,"(Rasmussen et al., 2010)",Unknown,Unknown,<18Y,,Patient,NM_000551.3:Unknown,"NM_000551.3:c.Unknown: char 14: expected one of (, *, or a digit",,,,,,,,,,,,,,,,,,,,,,,
Yes,20064270,362,No,c.362A>G,NM_000551.3,p.Asp121Gly,D121G(c.362A>G),missense_variant,12,12,No,HP:0010797; HP:0009711; HP:0000107; HP:0001737; HP:0005584; HP:0002666,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,"17 families (n=109 individuals) were tested  for VHL mutations. Mutation analysis was performed by direct sequencing of the VHL gene. Mutations were identified in 36 patients. Mutations-carriers were screened for VHL disease-related tumors and were offered follow-up annual examinations. Tumor status and phenotypes were documented at initial screening and at follow ups. 1 individual from family 12 was tested positive for p.D121G mutation. 2 Hemangioblastoma, bilateral retinal capillary hemangioma, renal cysts, pancreatic cysts,1 renal cell carcinoma and 1 pheochromocytoma were diagnosed at initial screening. The status remained the same at the last follow up. ACMG evidence codes:  'PP4' because the patient's phenotypes are highly specific for a disease with single genetic etiology.",Patient,NM_000551.3:c.362A>G,,NM_000551.3:c.362A>G,,,NG_008212.3:g.9901A>G,LRG_322:g.9901A>G,LRG_322t1:c.362A>G,NP_000542.1(LRG_322p1):p.(Asp121Gly),NC_000003.11:g.10188219A>G,3,10188219,.,A,G,NC_000003.12:g.10146535A>G,3,10146535,.,A,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,481,No,c.481C>T,NM_000551.3,p.Arg161*,R161*(c.481C>T),stop_gained,16,16,No,HP:0010797; HP:0000107; HP:0001737,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,"17 families (n=109 individuals) were tested  for VHL mutations. Mutation analysis was performed by direct sequencing of the VHL gene. Mutations were identified in 36 patients. Mutations-carriers were screened for VHL disease-related tumors and were offered follow-up annual examinations. Tumor status and phenotypes were documented at initial screening and at follow ups. 1 individual from family 16 was tested positive for p.R161X mutation. 3 hemangioblastoma, renal cysts, pancreatic cysts were diagnosed at initial screening. The status remained the same at the last follow up.  ACMG evidence codes:  'PP4' because the patient's phenotypes are highly specific for a disease with single genetic etiology.",Patient,NM_000551.3:c.481C>T,,NM_000551.3:c.481C>T,,,NG_008212.3:g.13170C>T,LRG_322:g.13170C>T,LRG_322t1:c.481C>T,NP_000542.1(LRG_322p1):p.(Arg161Ter),NC_000003.11:g.10191488C>T,3,10191488,.,C,T,NC_000003.12:g.10149804C>T,3,10149804,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,256,No,c.256C>T,NM_000551.3,p.Pro86Ser,P86S(c.256C>T),missense_variant,19,19,No,HP:0010797;HP:0000107; HP:0001737; HP:0005584; HP:0030393,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,"17 families (n=109 individuals) were tested  for VHL mutations. Mutation analysis was performed by direct sequencing of the VHL gene. Mutations were identified in 36 patients. Mutations-carriers were screened for VHL disease-related tumors and were offered follow-up annual examinations. Tumor status and phenotypes were documented at initial screening and at follow ups. 1 individual from family 19 was tested positive for p.P86S mutation. 1 Hb, KC, PC, 1 RCC were diagnosed at initial screening. 1 additional RCC, 1 Hb and ELST were diagnosed at follow ups. The patients deceased at last follow up. 1 individual from family 43 was also tested positive for p.P86S mutation. 1 hemangioblastoma was diagnosed at initial screening. 3 more hemangioblastomas, 2 renal cell carcinoma, pancreatic cancer and 1 pheochromocytoma were diagnosed at follow-ups.  ACMG evidence codes:  'PP4' because the patients' family history are highly specific for a disease with single genetic etiology.",Patient,NM_000551.3:c.256C>T,,NM_000551.3:c.256C>T,,,NG_008212.3:g.5469C>T,LRG_322:g.5469C>T,LRG_322t1:c.256C>T,NP_000542.1(LRG_322p1):p.(Pro86Ser),NC_000003.11:g.10183787C>T,3,10183787,.,C,T,NC_000003.12:g.10142103C>T,3,10142103,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,256,No,c.256C>T,NM_000551.3,p.Pro86Ser,P86S(c.256C>T),missense_variant,43,43,No,HP:0010797; HP:0005584; HP:0002894; HP:0002666,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,,Patient,NM_000551.3:c.256C>T,,NM_000551.3:c.256C>T,,,NG_008212.3:g.5469C>T,LRG_322:g.5469C>T,LRG_322t1:c.256C>T,NP_000542.1(LRG_322p1):p.(Pro86Ser),NC_000003.11:g.10183787C>T,3,10183787,.,C,T,NC_000003.12:g.10142103C>T,3,10142103,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,485,No,c.485G>T,NM_000551.3,p.Cys162Phe,C162F(c.485G>T),missense_variant,20,20,No,HP:0010797; HP:0009711; HP:0000107; HP:0001737; HP:0005584; HP:0002666,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,"17 families (n=109 individuals) were tested  for VHL mutations. Mutation analysis was performed by direct sequencing of the VHL gene. Mutations were identified in 36 patients. Mutations-carriers were screened for VHL disease-related tumors and were offered follow-up annual examinations. Tumor status and phenotypes were documented at initial screening and at follow ups. 1 individual from family 20 was tested positive for p.C162F mutation. 2 hemangioblastoma, unilateral retinal capillary hemangioma, kidney cysts, pancreatic cysts and 1 pheochromocytoma were diagnosed at initial screening. 1 renal cell carcinoma and 1 pheochromocytoma were detected at follow-ups. ACMG evidence codes:  'PP4' because the patient's phenotypes are highly specific for a disease with single genetic etiology.",Patient,NM_000551.3:c.485G>T,,NM_000551.3:c.485G>T,,,NG_008212.3:g.13174G>T,LRG_322:g.13174G>T,LRG_322t1:c.485G>T,NP_000542.1(LRG_322p1):p.(Cys162Phe),NC_000003.11:g.10191492G>T,3,10191492,.,G,T,NC_000003.12:g.10149808G>T,3,10149808,.,G,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,245,No,c.245G>C,NM_000551.3,p.Arg82Pro,R82P(c.245G>C),missense_variant,21,21,No,HP:0010797; HP:0009711; HP:0000107; HP:0001737; HP:0005584,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,"17 families (n=109 individuals) were tested  for VHL mutations. Mutation analysis was performed by direct sequencing of the VHL gene. Mutations were identified in 36 patients. Mutations-carriers were screened for VHL disease-related tumors and were offered follow-up annual examinations. Tumor status and phenotypes were documented at initial screening and at follow ups. 1 individual from family 21 was tested positive for p.R82P mutation. 1 hemangioblastoma was diagnosed at initial screening, 2 additional hemangioblastoma, bilateral RA, KC, PC, 1 RCC were diagnosed at follow-ups. The patient deceased at last follow-up. ACMG evidence codes:  'PP4' because the patient's phenotypes are highly specific for a disease with single genetic etiology.",Patient,NM_000551.3:c.245G>C,,NM_000551.3:c.245G>C,,,NG_008212.3:g.5458G>C,LRG_322:g.5458G>C,LRG_322t1:c.245G>C,NP_000542.1(LRG_322p1):p.(Arg82Pro),NC_000003.11:g.10183776G>C,3,10183776,.,G,C,NC_000003.12:g.10142092G>C,3,10142092,.,G,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,,no,,NM_000551.3,p.Glu134*,E134X,stop_gained,23,23,No,HP:0010797; HP:0009711; HP:0000107; HP:0005584,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,"17 families (n=109 individuals) were tested  for VHL mutations. Mutation analysis was performed by direct sequencing of the VHL gene. Mutations were identified in 36 patients. Mutations-carriers were screened for VHL disease-related tumors and were offered follow-up annual examinations. Tumor status and phenotypes were documented at initial screening and at follow ups. 3  adult members from family 23 were tested positive for p.E134X mutation. 1 patient was affected by 2 Hb, Bilat RA, KC, 1 RCC. 2 other members were asymptomatic both at initial screening and follow up. ACMG evidence codes:  'PP4' because the patient's phenotypes are highly specific for a disease with single genetic etiology.",Patient,NM_000551.3:Unknown,"NM_000551.3:c.Unknown: char 14: expected one of (, *, or a digit",,,,,,,,,,,,,,,,,,,,,,,
Yes,20064270,,No,,NM_000551.3,p.Glu134*,E134X,stop_gained,23,23,No,none,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,,Patient,NM_000551.3:Unknown,"NM_000551.3:c.Unknown: char 14: expected one of (, *, or a digit",,,,,,,,,,,,,,,,,,,,,,,
Yes,20064270,,No,,NM_000551.3,p.Glu134*,E134X,stop_gained,23,23,No,none,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,,Patient,NM_000551.3:Unknown,"NM_000551.3:c.Unknown: char 14: expected one of (, *, or a digit",,,,,,,,,,,,,,,,,,,,,,,
Yes,20064270,266,No,c.266T>C,NM_000551.3,p.Leu89Pro,L89P(c.266T>C),missense_variant,53,53,No,HP:0000107; HP:0001737; HP:0010797,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,17 families (n=109 individuals) were tested  for VHL mutations. Mutation analysis was performed by direct sequencing of the VHL gene. Mutations were identified in 36 patients. Mutations-carriers were screened for VHL disease-related tumors and were offered follow-up annual examinations. Tumor status and phenotypes were documented at initial screening and at follow ups. 1 individual from family 53 was tested positive for p.L89P mutation. kidney cysts and pancreatic cysts were diagnosed at initial screening. 1 hemangioblastoma was detected at follow-ups.ACMG evidence codes:  'PP4' because the patient's phenotypes are highly specific for a disease with single genetic etiology.,Patient,NM_000551.3:c.266T>C,,NM_000551.3:c.266T>C,,,NG_008212.3:g.5479T>C,LRG_322:g.5479T>C,LRG_322t1:c.266T>C,NP_000542.1(LRG_322p1):p.(Leu89Pro),NC_000003.11:g.10183797T>C,3,10183797,.,T,C,NC_000003.12:g.10142113T>C,3,10142113,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,6,6,No,HP:0010797; HP:0009711,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,"17 families (n=109 individuals) were tested  for VHL mutations. Mutation analysis was performed by direct sequencing of the VHL gene. Mutations were identified in 36 patients. Mutations-carriers were screened for VHL disease-related tumors and were offered follow-up annual examinations. Tumor status and phenotypes were documented at initial screening and at follow ups. 6 (3 adults and 3 children) members from family 6 were tested positive with c.99_100InsA mutation. 2 adult  and 1 pediatric patients were affected at initial screening. Another adult patient was affected by VHL disease at follow up. 2 children were asymptomatic both at initial screening and at last follow up. 13 (7 adults and 6 children) members from family 7 were tested positive with c.99_100InsA mutation.  9 members were affected by clinical VHL disease, 4 pediatric patients were asymptomatic at last follow up. ACMG evidence codes:  'PP4' because the patients' family history are highly specific for a disease with single genetic etiology.

",Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,6,6,No,HP:0010797; HP:0009711; HP:0000107; HP:0001737,"(Rasmussen et al., 2010)",Unknown,Unknown,<18Y,,Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,6,6,No,HP:0010797; HP:0009711; HP:0000107; HP:0001737; HP:0005584,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,,Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,6,6,No,HP:0010797,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,,Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,6,6,No,none,"(Rasmussen et al., 2010)",Unknown,Unknown,<18Y,,Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,6,6,No,none,"(Rasmussen et al., 2010)",Unknown,Unknown,<18Y,,Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,7,7,No,HP:0030424,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,,Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,7,7,No,none,"(Rasmussen et al., 2010)",Unknown,Unknown,<18Y,,Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,7,7,No,HP:0010797; HP:0005584; HP:0000107; HP:0001737,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,,Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,7,7,No,HP:0010797,"(Rasmussen et al., 2010)",Unknown,Unknown,<18Y,,Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,7,7,No,HP:0010797; HP:0000107; HP:0001737,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,,Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,7,7,No,none,"(Rasmussen et al., 2010)",Unknown,Unknown,<18Y,,Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,7,7,No,HP:0010797; HP:0000107; HP:0001737,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,,Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,7,7,No,HP:0010797,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,,Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,7,7,No,HP:0010797,"(Rasmussen et al., 2010)",Unknown,Unknown,<18Y,,Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,7,7,No,none,"(Rasmussen et al., 2010)",Unknown,Unknown,<18Y,,Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,7,7,No,HP:0010797; HP:0000107; HP:0001737; HP:0005584,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,,Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,7,7,No,HP:0010797; HP:0000107; HP:0001737,"(Rasmussen et al., 2010)",Unknown,Unknown,>18Y,,Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,20064270,99,No,c.99_100insA,NM_000551.3,p.Gly34Argfs*98,G34Rfs*98 (c.99_100insA),plus_1_frameshift_variant,7,7,No,none,"(Rasmussen et al., 2010)",Unknown,Unknown,<18Y,,Patient,NM_000551.3:c.99_100insA,,NM_000551.3:c.99_100insA,,,NG_008212.3:g.5312_5313insA,LRG_322:g.5312_5313insA,LRG_322t1:c.99_100insA,NP_000542.1(LRG_322p1):p.(Gly34ArgfsTer98),NC_000003.11:g.10183630_10183631insA,3,10183630,.,G,GA,NC_000003.12:g.10141946_10141947insA,3,10141946,.,G,GA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,11850836,Unknown,No,Unknown,NM_000551.3,Unknown,deletion,deletion,case 1,1,No,HP:0005584,"(Vortmeyer et al., 2002)",Unknown,Unknown,,"Tumor samples from 3 unrelated patients with germline deletion of VHL gene were analyzed for genetic changes in the second copy of the VHL gene.
Case 1 patient has germline deletion of VHL gene demonstrated by loss of one open-reading frame signal detected by g7 cDNA probe. Renal cell carcinoma sample from this patient shows a missense mutation I151S(c.452T>G) in the second copy of VHL gene. 
Case 2 patient has germline deletion on chromosome 3 (>35kb, <90kb) resulting in complete loss of VHL gene. Hemangioblastoma from this patient shows a missense mutation R200Y(c.598C>T) in the second copy of VHL gene.
Case 3 patient has germline deletion on chromosome 3 (>35kb, <90kb) resulting in complete loss of VHL gene. Renal cell carcinoma sample from this patient shows a missense mutation R69C(c.205C>T) in the second copy of VHL gene.
ACMG: 'PP4' because the patients' phenotypes is highly specific for a disease with single genetic etiology.",Tumour,NM_000551.3:Unknown,"NM_000551.3:c.Unknown: char 14: expected one of (, *, or a digit",,,,,,,,,,,,,,,,,,,,,,,
Yes,11850836,Unknown,No,Unknown,NM_000551.3,Unknown,deletion,deletion,case 2,2,No,HP:0010797,"(Vortmeyer et al., 2002)",Unknown,Unknown,,,Tumour,NM_000551.3:Unknown,"NM_000551.3:c.Unknown: char 14: expected one of (, *, or a digit",,,,,,,,,,,,,,,,,,,,,,,
Yes,11850836,Unknown,No,Unknown,NM_000551.3,Unknown,deletion,deletion,case 3,3,No,HP:0005584,"(Vortmeyer et al., 2002)",Unknown,Unknown,,,Tumour,NM_000551.3:Unknown,"NM_000551.3:c.Unknown: char 14: expected one of (, *, or a digit",,,,,,,,,,,,,,,,,,,,,,,
Yes,29616089,227,No,c.227_229delTCT,NM_000551.3,p.Phe76del,F76del(c.227_229delTCT),deletion,1,1,No,HP:0010797; HP:0000107;HP:0005584,"(Wang et al., 2018)",E35Y0M; lk38Y0M,M,,"A report of 3 cases of VHL diseases treated at the Affiliate Hospital of Zunyi Medical College (Zunyi, China) between September 2014 and October 2015. Case 1 patient was diagnosed with renal cell carcinoma and c.227_229delTCT mutation was detected in the VHL gene. The patient also presents with other phenotypes including hemangioblastoma, kidney cysts and neurofibromas. The mother of the index patient's decease may have been assoiciated with VHL. ACMG evidence codes: 'PP4' because the patients' family history are highly specific for a disease with single genetic etiology.",Patient,NM_000551.3:c.227_229delTCT,Removing redundant reference bases from variant description,NM_000551.3:c.227_229del,,,NG_008212.3:g.5440_5442del,LRG_322:g.5440_5442del,LRG_322t1:c.227_229del,NP_000542.1(LRG_322p1):p.(Phe76del),NC_000003.11:g.10183758_10183760del,3,10183754,.,ATCT,A,NC_000003.12:g.10142074_10142076del,3,10142070,.,ATCT,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29616089,499,no,c.499C>T,NM_000551.3,p.Arg167Trp,R167W (c.499C>T),missense_variant,2,2,No,HP:0010797;HP:0002666,"(Wang et al., 2018)",E37Y0M; lk41Y0M,M,right cerebellar hemangioblastoma; bilateral adrenal pheochromocytoma; 2 other sibilings were negative for the mutation,"A report of 3 cases of VHL diseases treated at the Affiliate Hospital of Zunyi Medical College (Zunyi, China) between September 2014 and October 2015. Cases 2 is a 41Y male patient presented with right cerebellar hemangioblastoma and bilateral adrenal pheochromocytoma. A mutation c.499C>T (p.Arg167Trp) was confirmed in the VHL gene. The patients brother and sister were also confirmed for the mutation, although the sister was asymptomatic and the brother had a nodule in the left cerebellar tonsil with a size of ~9.010.5 mm, which indicated the presence of a hemangioblastoma, astrocytoma or ependymoma. However, the diagnosis for the brother could not be confirmed. The patient had 2 other siblings that were negative for the mutation. The mother exhibited a brain tumor and coronary heart disease and has since passed. ACMG: 'PP4' because the patients' phenotypes and family history are highly specific for a disease with single genetic etiology.",Patient,NM_000551.3:c.499C>T,,NM_000551.3:c.499C>T,,,NG_008212.3:g.13188C>T,LRG_322:g.13188C>T,LRG_322t1:c.499C>T,NP_000542.1(LRG_322p1):p.(Arg167Trp),NC_000003.11:g.10191506C>T,3,10191506,.,C,T,NC_000003.12:g.10149822C>T,3,10149822,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29616089,499,no,c.499C>T,NM_000551.3,p.Arg167Trp,R167W (c.499C>T),missense_variant,2,2,No,Unknown,"(Wang et al., 2018)",Unknown,M,brother,,Patient,NM_000551.3:c.499C>T,,NM_000551.3:c.499C>T,,,NG_008212.3:g.13188C>T,LRG_322:g.13188C>T,LRG_322t1:c.499C>T,NP_000542.1(LRG_322p1):p.(Arg167Trp),NC_000003.11:g.10191506C>T,3,10191506,.,C,T,NC_000003.12:g.10149822C>T,3,10149822,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29616089,499,no,c.499C>T,NM_000551.3,p.Arg167Trp,R167W (c.499C>T),missense_variant,2,2,No,None,"(Wang et al., 2018)",Unknown,F,sister,,Patient,NM_000551.3:c.499C>T,,NM_000551.3:c.499C>T,,,NG_008212.3:g.13188C>T,LRG_322:g.13188C>T,LRG_322t1:c.499C>T,NP_000542.1(LRG_322p1):p.(Arg167Trp),NC_000003.11:g.10191506C>T,3,10191506,.,C,T,NC_000003.12:g.10149822C>T,3,10149822,.,C,T,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29616089,500,No,c.500G>A,NM_000551.3,p.Arg167Gln,R167Q(c.500G>A),missense_variant,3,3,No,HP:0000107,"(Wang et al., 2018)",lk38Y0M,M,right clear cell RCC; multiple small cystic lesions were detected in the left and right kidneys and pancreas,"A report of 3 cases of VHL diseases treated at the Affiliate Hospital of Zunyi Medical College (Zunyi, China) between September 2014 and October 2015. Cases 3 is a 38Y male patient presented with right clear cell RCC and multiple small cystic lesions in the left and right kidneys and pancreas. A mutation c.500G>A (p.Arg167Gln) was confirmed in the VHL gene. Familial genetic screening revealed the same mutation in his 2 sons, who had no abnormalities in the abdomen but refused MRI brain scanning. The patient's mother passed due to pancreatic cancer and genotypic information on the mother is not available. ACMG: 'PP4' because the patients' family history are highly specific for a disease with single genetic etiology.",Patient,NM_000551.3:c.500G>A,,NM_000551.3:c.500G>A,,,NG_008212.3:g.13189G>A,LRG_322:g.13189G>A,LRG_322t1:c.500G>A,NP_000542.1(LRG_322p1):p.(Arg167Gln),NC_000003.11:g.10191507G>A,3,10191507,.,G,A,NC_000003.12:g.10149823G>A,3,10149823,.,G,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29616089,500,No,c.500G>A,NM_000551.3,p.Arg167Gln,R167Q(c.500G>A),missense_variant,3,3,No,None,"(Wang et al., 2018)",Unknown,M,no abdnormalities in abdomen; brain MRI was declined by patient; son1,,Patient,NM_000551.3:c.500G>A,,NM_000551.3:c.500G>A,,,NG_008212.3:g.13189G>A,LRG_322:g.13189G>A,LRG_322t1:c.500G>A,NP_000542.1(LRG_322p1):p.(Arg167Gln),NC_000003.11:g.10191507G>A,3,10191507,.,G,A,NC_000003.12:g.10149823G>A,3,10149823,.,G,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,29616089,500,No,c.500G>A,NM_000551.3,p.Arg167Gln,R167Q(c.500G>A),missense_variant,3,3,No,None,"(Wang et al., 2018)",Unknown,M,no abdnormalities in abdomen; brain MRI was declined by patient; son2,,Patient,NM_000551.3:c.500G>A,,NM_000551.3:c.500G>A,,,NG_008212.3:g.13189G>A,LRG_322:g.13189G>A,LRG_322t1:c.500G>A,NP_000542.1(LRG_322p1):p.(Arg167Gln),NC_000003.11:g.10191507G>A,3,10191507,.,G,A,NC_000003.12:g.10149823G>A,3,10149823,.,G,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,22573489,193,No,c.193T>A,NM_000551.3,p.Ser65Thr,S65T(c.193T>A),missense_variant,N/A,Unknown,No,HP:0002666,"(Weber et al., 2012)",E14Y0M,M,Tumor ID 9,A series of 28 pheochromacytomas from 28 patients from the Freiburg International Pheochromaccytoma Registry were used to study for somatic point mutation variants and loss of heterozygosity. 9 out of 28 sampels were from VHL germline mutation carrier. VHL-associated pheochromocytoma samples were collected from 1 patient with germline missence (c.193T>A) VHL mutation. ACMG evidence codes:  'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.,Tumour,NM_000551.3:c.193T>A,,NM_000551.3:c.193T>A,,,NG_008212.3:g.5406T>A,LRG_322:g.5406T>A,LRG_322t1:c.193T>A,NP_000542.1(LRG_322p1):p.(Ser65Thr),NC_000003.11:g.10183724T>A,3,10183724,.,T,A,NC_000003.12:g.10142040T>A,3,10142040,.,T,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,22573489,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H(c.292T>C),missense_variant,N/A,Unknown,No,HP:0002666,"(Weber et al., 2012)",E70Y0M,F,Tumor ID 10,A series of 28 pheochromacytomas from 28 patients from the Freiburg International Pheochromaccytoma Registry were used to study for somatic point mutation variants and loss of heterozygosity. 9 out of 28 sampels were from VHL germline mutation carrier. VHL-associated pheochromocytoma samples were collected from 3 patients with germline missence (c.292T>C) VHL mutation. ACMG evidence codes:  'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.,Tumour,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,22573489,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H(c.292T>C),missense_variant,N/A,Unknown,No,HP:0002666,"(Weber et al., 2012)",E24Y0M,F,Tumor ID 11,,Tumour,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,22573489,292,No,c.292T>C,NM_000551.3,p.Tyr98His,Y98H(c.292T>C),missense_variant,N/A,Unknown,No,HP:0002666,"(Weber et al., 2012)",E48Y0M,F,Tumor ID 12,,Tumour,NM_000551.3:c.292T>C,,NM_000551.3:c.292T>C,,,NG_008212.3:g.5505T>C,LRG_322:g.5505T>C,LRG_322t1:c.292T>C,NP_000542.1(LRG_322p1):p.(Tyr98His),NC_000003.11:g.10183823T>C,3,10183823,.,T,C,NC_000003.12:g.10142139T>C,3,10142139,.,T,C,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,22573489,482,No,c.482G>A,NM_000551.3,p.Arg161Gln,R161Q(c.482G>A),missense_variant,N/A,Unknown,No,HP:0002666,"(Weber et al., 2012)",E14Y0M,M,Tumor ID 13,A series of 28 pheochromacytomas from 28 patients from the Freiburg International Pheochromaccytoma Registry were used to study for somatic point mutation variants and loss of heterozygosity. 9 out of 28 sampels were from VHL germline mutation carrier. VHL-associated pheochromocytoma samples were collected from 1 patient with germline missence (c.482G>A) VHL mutation. ACMG evidence codes:  'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.,Tumour,NM_000551.3:c.482G>A,,NM_000551.3:c.482G>A,,,NG_008212.3:g.13171G>A,LRG_322:g.13171G>A,LRG_322t1:c.482G>A,NP_000542.1(LRG_322p1):p.(Arg161Gln),NC_000003.11:g.10191489G>A,3,10191489,.,G,A,NC_000003.12:g.10149805G>A,3,10149805,.,G,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,22573489,500,No,c.500G>A,NM_000551.3,p.Arg167Gln,R167Q(c.500G>A),missense_variant,N/A,Unknown,No,HP:0002666,"(Weber et al., 2012)",E27Y0M,F,Tumor ID 14,A series of 28 pheochromacytomas from 28 patients from the Freiburg International Pheochromaccytoma Registry were used to study for somatic point mutation variants and loss of heterozygosity. 9 out of 28 sampels were from VHL germline mutation carrier. VHL-associated pheochromocytoma samples were collected from 1 patient with germline missence (c.500G>A) VHL mutation. ACMG evidence codes:  'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.,Tumour,NM_000551.3:c.500G>A,,NM_000551.3:c.500G>A,,,NG_008212.3:g.13189G>A,LRG_322:g.13189G>A,LRG_322t1:c.500G>A,NP_000542.1(LRG_322p1):p.(Arg167Gln),NC_000003.11:g.10191507G>A,3,10191507,.,G,A,NC_000003.12:g.10149823G>A,3,10149823,.,G,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,22573489,533,No,c.533T>A,NM_000551.3,p.Leu178Gln,L178Q(c.533T>A),missense_variant,N/A,Unknown,No,HP:0002666,"(Weber et al., 2012)",E24Y0M,F,Tumor ID 15,A series of 28 pheochromacytomas from 28 patients from the Freiburg International Pheochromaccytoma Registry were used to study for somatic point mutation variants and loss of heterozygosity. 9 out of 28 sampels were from VHL germline mutation carrier. VHL-associated pheochromocytoma samples were collected from 1 patient with germline missence (c.533T>A) VHL mutation. ACMG evidence codes:  'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.,Tumour,NM_000551.3:c.533T>A,,NM_000551.3:c.533T>A,,,NG_008212.3:g.13222T>A,LRG_322:g.13222T>A,LRG_322t1:c.533T>A,NP_000542.1(LRG_322p1):p.(Leu178Gln),NC_000003.11:g.10191540T>A,3,10191540,.,T,A,NC_000003.12:g.10149856T>A,3,10149856,.,T,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,22573489,640,No,c.640T>G,NM_000551.3,p.*214Gln,*214G(c.640T>G),stop_lost,N/A,Unknown,No,HP:0002666,"(Weber et al., 2012)",E20Y0M,M,"Tumor ID 16, mutation in stop codon",A series of 28 pheochromacytomas from 28 patients from the Freiburg International Pheochromaccytoma Registry were used to study for somatic point mutation variants and loss of heterozygosity. 9 out of 28 sampels were from VHL germline mutation carrier. VHL-associated pheochromocytoma samples were collected from 1 patient with germline missence (c.640T>G) VHL mutation. ACMG evidence codes:  'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.,Tumour,NM_000551.3:c.640T>G,,NM_000551.3:c.640T>G,,,NG_008212.3:g.13329T>G,LRG_322:g.13329T>G,LRG_322t1:c.640T>G,NP_000542.1(LRG_322p1):p.(Ter214GlyextTer14),NC_000003.11:g.10191647T>G,3,10191647,.,T,G,NC_000003.12:g.10149963T>G,3,10149963,.,T,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes,22573489,Unknown,No,Exon 2 del,NM_000551.3,Exon 2 del,Exon 2 deletion,exon_loss_variant,N/A,Unknown,No,HP:0002666,"(Weber et al., 2012)",E18Y0M,M,Tumor ID 17,A series of 28 pheochromacytomas from 28 patients from the Freiburg International Pheochromaccytoma Registry were used to study for somatic point mutation variants and loss of heterozygosity. 9 out of 28 sampels were from VHL germline mutation carrier. VHL-associated pheochromocytoma samples were collected from 1 patient with germline deletion of VHL Exon 2 VHL. ACMG evidence codes:  'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.,Tumour,NM_000551.3:Exon,"NM_000551.3:c.Exon: char 14: expected one of (, *, or a digit",,,,,,,,,,,,,,,,,,,,,,,
Yes,12673678,639,No,c.639T>G,NM_000551.3,p.Asp213Glu,D213E (c.639T>G),missense_variant,1,1,No,HP:0002666,"(Dannenberg et al., 2003)",lk49Y0M,F,Data previously published in Dannenberg 2000,A 49 year old female from Europe presented with pheochromocytoma. Genetic testing confirmed a germline missense mutation found at c.639T>G in the VHL gene. Family history is unknown. This patient underwent surgical resection. ACMG: PP4.,Tumour,NM_000551.3:c.639T>G,,NM_000551.3:c.639T>G,,,NG_008212.3:g.13328T>G,LRG_322:g.13328T>G,LRG_322t1:c.639T>G,NP_000542.1(LRG_322p1):p.(Asp213Glu),NC_000003.11:g.10191646T>G,3,10191646,.,T,G,NC_000003.12:g.10149962T>G,3,10149962,.,T,G,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
To be re-run through variant validator,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Yes - c. updated,11850829,322,No,c.322_324dupCGC,NM_000551.3,p.Arg108_Ile109insArg,R108_I109insR (c.322_324dupCGC),inframe_insertion,N/A,Unknown,No,HP:0010797,"(Lui et al., 2002)",Unknown,Unknown,"VHL associated hemangioblastoma, Patient I",36 VHL-related pheochromocytomas (from 21 patients) and 10 VHL-related CNS hemangioblastomas (from 6 patients) were studied using comparative genomic hybridization (CGH) to detect genetic imbalances. Patient I in VHL-Associated hemangioblastoma was found with germline insertion mutation (c.316insGCC) in the VHL gene. ACMG evidence codes:  'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.,Tumour,NM_000551.3:c.322_324dupCGC,Removing redundant reference bases from variant description,NM_000551.3:c.322_324dup,,,NG_008212.3:g.5535_5537dup,LRG_322:g.5535_5537dup,LRG_322t1:c.322_324dup,NP_000542.1:p.(Arg108dup),NC_000003.11:g.10183853_10183855dup,3,10183847,.,G,GGCC,NC_000003.12:g.10142169_10142171dup,3,10142163,.,G,GGCC,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes - c. slightly updated,12644949,572,No,c.572_592dup,NM_000551.3,p.His191_Asp197dup,H191_D197dup (c.572_592dup),inframe_insertion,N/A,Unknown,No,"HP:0009711; HP:0001028; HP:0002666, HP:0010797","(Miyagawa et al., 2003)",lk46Y0M; E17Y0M,F,,"A case report on a 46-year old women diagnosed with clinical VHL disease at Hirosaki University Hospital, Japan. A new 21 nucleotide duplication mutation in the VHL gene was identified. Her elder brother died of hypertensive disease associated with pheochromocytoma and bilateral retinal hemangioma. ACMG: 'PP1' because cosegregation with disease in siblings (multiple affected family members) in a gene definitively known to cause the disease.",Patient,NM_000551.3:c.572_592dup,,NM_000551.3:c.572_592dup,,,NG_008212.3:g.13261_13281dup,LRG_322:g.13261_13281dup,LRG_322t1:c.572_592dup,NP_000542.1:p.(His191_Asp197dup),NC_000003.11:g.10191579_10191599dup,3,10191572,.,G,GAAGACCACCCAAATGTGCAGA,NC_000003.12:g.10149895_10149915dup,3,10149888,.,G,GAAGACCACCCAAATGTGCAGA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes - c. slightly updated,12644949,572,No,c.572_592dup,NM_000551.3,p.His191_Asp197dup,H191_D197dup (c.572_592dup),inframe_insertion,N/A,Unknown,No,HP:0002666; HP:0009711,"(Miyagawa et al., 2003)",Unknown,M,Elder brother,,Patient,NM_000551.3:c.572_592dup,,NM_000551.3:c.572_592dup,,,NG_008212.3:g.13261_13281dup,LRG_322:g.13261_13281dup,LRG_322t1:c.572_592dup,NP_000542.1:p.(His191_Asp197dup),NC_000003.11:g.10191579_10191599dup,3,10191572,.,G,GAAGACCACCCAAATGTGCAGA,NC_000003.12:g.10149895_10149915dup,3,10149888,.,G,GAAGACCACCCAAATGTGCAGA,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes - c. slightly updated,12673678,641,No,c.641_642insC,NM_000551.3,p.*214Cysext*41,*214Cext*41 (c.641_642insC),frameshift_variant,2,2,No,HP:0002666,"(Dannenberg et al., 2003)",unknown,F,Data previously published in Dannenberg 2000,"A female of unknown age from Europe presented with pheochromocytoma. Genetic testing confirmed a germline frameshift mutation found at c.641insC in the VHL gene. Family history is unknown. This patient underwent surgical resection. ACMG: PM4, PP4.",Tumour,NM_000551.3:c.641_642insC,,NM_000551.3:c.641_642insC,,,NG_008212.3:g.13330_13331insC,LRG_322:g.13330_13331insC,LRG_322t1:c.641_642insC,NP_000542.1:p.(Ter214CysextTer41),NC_000003.11:g.10191648_10191649insC,3,10191648,.,G,GC,NC_000003.12:g.10149964_10149965insC,3,10149964,.,G,GC,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",
Yes - c. updated,23913169,464-1,No,c.464-1G>A,NM_000551.3,Unknown,c.464-1G>A,splice_site_variant,None,None,No,HP:0030405; HP:0001737; HP:0002666; HP:0010797,"(Gucer et al., 2013)",lk60Y0M,F,,"A 60Y F with a known history of VHL disease (c.464-1G>A mutation) was found to have multiple pancreatic cysts and 2 pancreatic endocrine tumors. She had undergone previous treatment for pheochromocytoma, cystic pancreatic lesion, and cerebral hemangioblastoma. She was found recently to have a small L renal mass undergoing surveillance. ACMG: 'PP4' because the patients' phenotypes are highly specific for a disease with single genetic etiology.",Patient,NM_000551.3:c.464-1G>A,,NM_000551.3:c.464-1G>A,NC_000003.11(NM_000551.3):c.464-1G>A,NG_008212.3(NM_000551.3):c.464-1G>A,NG_008212.3:g.13152G>A,LRG_322:g.13152G>A,LRG_322t1:c.464-1G>A,NP_000542.1:p.?,NC_000003.11:g.10191470G>A,3,10191470,.,G,A,NC_000003.12:g.10149786G>A,3,10149786,.,G,A,VHL,HGNC:12687,"Homo sapiens von Hippel-Lindau tumor suppressor (VHL), transcript variant 1, mRNA",